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Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a poor prognosis and 
limited treatment options. In recent years, chimeric antigen receptor (CAR) T cells have 
achieved remarkable success in the treatment of liquid malignancies but efficacy in solid 
malignancies is limited to date. A major hurdle is the lack of tumor specific targets. We aimed 
to address this issue in the case of PDAC by analyzing the expression of almost 400 cell-surface 
antigens on tumor cells of different patient derived xenograft (PDX) mouse models. Identified 
candidates were prioritized with respect to their off-tumor expression bioinformatically by 
using RNA and protein expression databases. The specificity of these target candidates was 
further validated on primary PDAC specimens using flow cytometry and a newly developed 
cyclic immunofluorescence (cyclic IF) microscopy technology. We identified Cutaneous 
Lymphocyte Antigen (CLA), CEACAM6 (CD66c), CDCP1 (CD318) and Tetraspanin-8 
(TSPAN8) as having high specificity to tumor cells and restricted off-tumor expression. In 
addition, we investigated the expression of these targets using flow cytometry and cyclic IF 
microscopy on healthy tissue arrays. Target expression on healthy tissues was very restricted, 
which further underlined the quality of the novel target candidates. We generated CAR 
constructs differing in spacer length (XS, S, M, L) and scFv orientation (Vh-Vl, Vl-Vh) for each 
target candidate and thoroughly validated these CARs in co-culture assays that utilized 
cytotoxicity, activation marker expression and cytokine release as readouts. All CLA CARs 
were dysfunctional due to self-antigenicity on activated T cells. The most promising constructs 
for the other target candidates were evaluated in two pre-clinical PDAC mouse models. This 
revealed CD318 Vh-Vl XS, CD66c Vl-Vh XS and TSPAN8 Vh-Vl S as the most effective CAR 
constructs of the remaining targets. During CAR development we observed inferior in vivo 
functionality of long IgG-based spacers compared to their in vitro performance. It has been 
shown that these spacers convey unspecific binding in murine models. However, long spacers 
are regarded as beneficial when targeting membrane proximal epitopes. Thus, we evaluated a 
novel class of long spacers, derived from the SIGLEC family, with similar structural attributes 
as the IgG family but lack the natural unspecific binding sites. In non-solid and solid tumor 
settings, a novel SIGLEC-4 based spacer demonstrated superior functionality over long IgG 
spacers in vitro and in vivo with favorable activation marker expression and cytokine release 
for putative subsequent clinical applications. In summary, this project led to the identification 
of novel target candidates for PDAC and establishment of a set of highly functional target-
specific CARs that may pave the road for later clinical application and hopefully will help 




1.1. Pancreatic cancer  
Pancreatic cancer is the fourth most common cause of cancer associated death in Western 
countries (Ferlay et al., 2018). Improvements in the treatment of other cancer entities as well as 
an aging society is supposed to cause pancreatic cancer becoming the second leading cause of 
cancer related mortality by 2030 (Rahib et al., 2014). The five-year overall survival rate has 
improved from 5% to 8% in the last decade; however, this encouraging trend is not based on 
the development of new therapeutic approaches (Siegel et al., 2012; Siegel et al., 2018; Lai et 
al., 2019). Chemotherapy remains the main pillar of pancreatic cancer treatment (Kleeff et al., 
2016). Until today, surgery is the only potential curative intervention and has evolved from a 
high-risk procedure to a difficult but manageable procedure in specialized centers (Hartwig et 
al., 2013). However, only 20% of the patients present a resectable tumor at the timepoint of 
diagnosis, mainly because the remaining cases have already entered a non-resectable or 
metastatic stage, which frequently occurs due to lack of disease specific symptoms (Gillen et 
al., 2010; Werner et al., 2013). Genetic predisposition and lifestyle related factors influencing 
development of pancreatic cancer are known, yet they explain only a minor fraction of the actual 
incidence number. A familial history of pancreatic cancer can be found in 10% of the patients 
(Turati et al., 2013). Genetic mutations most commonly affect the genes BRCA2, BRCA1, 
PALB2, CDKN2A, ATM, TP53, MLH1, MSH2, MSH6 (Pihlak et al., 2017). Smoking (Parkin, 
2011; Bosetti et al., 2012; Whiteman et al., 2015), obesity, low activity (Behrens et al., 2015; 
Genkinger et al., 2015), nutritional factors (Larsson and Wolk, 2012; Bosetti et al., 2013; 
Rohrmann et al., 2013) and diabetes (Bosetti et al., 2014) are linked to increased lifetime risks. 
However, the field is being far away from a comprehensive understanding of the biology of 
pancreatic cancer, and with therapeutic advancements failing to keep pace with the rising 
incidence, there is an urgent need for novel therapeutic options.  
1.2. The healthy pancreas and pancreatic ductal adenocarcinoma 
development 
The healthy pancreas consists of an exocrine and an endocrine compartment, of which the 
former is producing digestive enzymes and the latter one regulates pancreatic hormone 
secretion. The endocrine cells steer glucose homeostasis by secreting hormones into the 
bloodstream. They arrange in clusters called Langerhans islets and comprise α-, β-, δ-, ε- and 
PP-cells. The exocrine compartment consists of acinar cells secreting zymogens that are locally 
neutralized by bicarbonate producing ductal epithelial cells and transported to the duodenum 
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(Cleveland et al., 2012).  Situated in between these two cell types are the centro-acinar cells, 
which are suggested to act as stem cell-like progenitors for endocrine and exocrine fates (Rovira 
et al., 2010; Kopinke et al., 2012). From each of these cell types malignancies may arise. 
However, pancreatic ductal adenocarcinoma (PDAC) is by far the most common neoplasm of 
the pancreas. It emanates from the aforementioned ductal epithelial or ductal-like cells and 
accounts for about 80% of all tumors of the pancreas (Kleeff et al., 2016).  
The development of PDAC is likely to start with acinar-to-ductal metaplasia (ADM) (Kanda et 
al., 2012; Sethi et al., 2017). Initiated by environmental stress conditions, such as inflammation 
or damaged tissue, acinar cells transdifferentiate to phenotypically epithelial cells (Kopp et al., 
2012; Wang et al., 2019). This requires the reprogramming of the cells to stem cell-like fates, 
rendering them more susceptible towards mutations due to increased proliferation. A key 
mutation towards PDAC development is the activation of the GTPase KRAS (Fig. 1). 95% of 
carcinomas derived from the exocrine pancreas compartment contain KRAS mutations 
(Almoguera et al., 1988). Studies conducted with transgenic mice bearing KRAS activating 
mutations showed formation of PDAC precursor lesions and periductal inflammation, but did 
not develop PDAC (Brembeck et al., 2003; Grippo et al., 2003). These precursor lesions, 
pancreatic intra-epithelial neoplasia (PanINs), are commonly regarded as evolutionary 
forerunners of PDAC (Makohon-Moore et al., 2018). These findings underline the importance 
of KRAS mutations in the oncogenesis of PDAC but show at same time that KRAS activation 
alone is not sufficient for PDAC establishment. Several more mutations must be accumulated 
during different PanIN stages, increasing the aggressiveness of cell growth until invasive PDAC 
is formed. In the last years, a strong body of genome sequencing studies has elucidated that 
besides KRAS, genetic alterations can be found in the tumor suppressor genes TP53, SMAD4 
and CDKN2A in around 50% to 80% of PDAC patients (Waddell et al., 2015; Witkiewicz et 
al., 2015; Bailey et al., 2016). Other mutations are highly heterogeneous among patients but 
also within a single patient at different lesion sides (Witkiewicz et al., 2015; Cancer Genome 




Figure 1: Proposed process of pancreatic ductal adenocarcinoma (PDAC) development.  PDAC has its origin 
either in ductal cells or in acinar cells that underwent acinar-to-ductal metaplasia (ADM) beforehand. Activating 
mutations of the KRAS gene are found in >90% of PDACs (Almoguera et al., 1988). The KRAS mutation is 
sufficient for induction of precursor lesions called pancreatic intraepithelial neoplasia (PanIN) (Brembeck et al., 
2003). Over time, mutations of CDKN2A, TP53 and SMAD4 accumulate leading to a higher degree of 
desmoplasia through the different PanIN stages. Aggressiveness increases until PDAC is formed. Modified from 
(Orth et al., 2019). 
 
1.3. Current treatment options 
At the time of diagnosis, patients are stratified according to the tumor stage and patient 
performance status (Neoptolemos et al., 2018). Tumor stages are categorized as: 1.) Resectable, 
2.) Borderline-resectable/Locally advanced unresectable and 3.) Metastatic. Patient status is 
normally evaluated based on the Eastern Cooperative Oncology Group (ECOG) score (Oken et 
al., 1982). The ECOG score ranges between 0 and 5. While 0 means the patient is asymptomatic, 
death is categorized as 5. ECOG score of 1 means the patient is symptomatic but not heavily 
restricted in life style. ECOG 2 indicates that the patient lies less than 50% of the time in bed 
but is not able to carry out work activities. A score of 3 means a confinement of more than 50% 
of the time to a bed or chair, while a score of 4 indicates the patient is only bedbound.  PDAC 
is mainly asymptomatic during early stages of development, which often leads to its late 
detection. This has unfortunate implications for the patients, as outcomes and treatment efficacy 
are more efficient at early stages when the tumor is operable. When the carcinoma is borderline 
resectable, the primary aim is decreasing the tumor’s critical mass to enable surgery. If the 
tumor is irresectable or metastatic, the only option so far is to offer the best palliative care. 
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1.3.1. Surgery  
Surgery remains the only potential curative therapeutic option. However, diagnosis is often 
made when the tumor already has vascular involvement or spread to neighboring organs (30-
40% of cases), or distant metastases are present (50-60% of cases) (Gillen et al., 2010; Werner 
et al., 2013) rendering a surgery obsolete.  Until very recently, surgery was frequently 
associated with unbearable morbidity and mortality (Bramhall et al., 1995), with unclear benefit 
on overall survival (Gudjonsson, 1995; Carpelan-Holmström et al., 2005). Therefore, tumor 
excisions were neglected as valid treatment options for a long time (Bilimoria et al., 2007). This 
changed with the emergence of more specialized centers and better perioperative handling, 
decreasing surgery-associated mortality rates below 5% (Hartwig et al., 2011). A complete 
pancreatectomy is avoided where possible because it leaves the patient with diabetes (Hartwig 
et al., 2015). Tumors located in the pancreatic tail are excised through a distal pancreatectomy 
and splenectomy, while neoplasms of the head are removed by a partial 
pancreaticoduodenectomy, also referred to as “Whipple procedure” (Diener et al., 2014). 
Although surgery offers the best chances for a curative setting, 90% of the patients relapse post-
surgery without any additional therapy (Griffin et al., 1990). Thus, adjuvant therapies have 
become standard-of-care follow-up procedures after tumor resection (Neoptolemos et al., 2004; 
Neoptolemos et al., 2010; Oettle et al., 2013).  
1.3.2. Adjuvant therapy 
A study that paved the way for usage of 5-fluorouracil (5-FU) in pancreatic cancer until today 
was conducted in the mid-1970s. The Gastrointestinal Tumor Study Group compared 5-FU and 
radiation as adjuvant therapy with a non-adjuvant control group. The median survival of the 
treatment group exceeded the control group’s median overall survival (mOS) by 9 months (20 
months versus 11 months) (Kalser and Ellenberg, 1985). Notably, although commonly applied 
in the adjuvant setting, radiation therapy provided no additional benefits over chemotherapy 
alone (Neoptolemos et al., 2004). In 2008 the CONKO-001 trial introduced gemcitabine as a 
second regimen for adjuvant chemotherapy (Neuhaus et al., 2008). Consequently, in 2010 the 
ESPAC-3 trial compared gemcitabine and 5-FU therapy and found no superiority of either one 
with respect to overall survival (Neoptolemos et al., 2010). Both groups exhibited a mOS of 23 
months. Later trials focused more on chemotherapeutics combining several agents. A 
breakthrough was achieved during the JASPAC-1 investigation in 2016, in which gemcitabine 
was compared to S-1, a combination of tegafur, gimeracil and oteracil. The S1 treated arm 
reached an unprecedented mOS of 46.5 months, while the gemcitabine monotherapy arm 
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reached 25.5 months (Uesaka et al., 2016). Although promising, these results were not yet 
confirmed in non-Asian populations. The current standard of care is FOLFIRINOX, either in 
the original formulation or in a modified version (mFOLFIRINOX) to reduce side effects. 
FOLFIRINOX consists of 5-FU, folinic acid, irinotecan and oxaliplatin. In the GI PRODIGE 
24 trial, published in 2018, the patient cohort post-operatively treated with FOLFIRINOX 
reached a mOS of 54.4 months. The gemcitabine monotherapy cohort reached a mOS of 35 
months (Conroy et al., 2018). Of note, the number of adverse events was higher within patients 
of the combination therapy cohort, most likely caused by the higher cytotoxic potential of 
FOLFIRINOX. Thus, it is advised to administer either gemcitabine monotherapy or 
gemcitabine/capecitabine dual therapy to patients with a bad performance status as shown in 
the ESPAC-4 trial (Neoptolemos et al., 2017). 
1.3.3. Neoadjuvant therapy 
Neoadjuvant therapy aims at preconditioning the tumor in order to allow for subsequent 
surgery. This is especially important for the 30-40% of the patients who present with a 
“borderline-resectable/locally advanced” tumor. These tumors have a lower resection rate due 
to vascular and surrounding organ involvement of the tumor. Neoadjuvant therapy can 
eliminate micro-metastases and decrease the tumor size (Seufferlein and Ettrich, 2019), which 
may potentially transform borderline-resectable tumors into resectable ones. Currently, there is 
no consensus about the most suitable treatment protocols, pre- and post-operative, which is in 
part due to missing high-quality data trials (Neoptolemos et al., 2018).  While pre-operative 
chemo- or chemoradiotherapy with gemcitabine alone or in combination with oxaliplatin 
(Heinrich et al., 2011; Tachezy et al., 2014; Versteijne et al., 2016) was investigated in the past, 
the rise of (m)FOLFIRINOX led to a shift from chemoradiotherapy to sole chemotherapy as 
pre-operative treatment (Katz et al., 2016). Since FOLFIRINOX contains 5-FU, gemcitabine is 
preferred in the subsequent adjuvant therapy. The results of the ESPAC-5F trial 
(ISRCTN89500674) comparing upfront surgery, chemoradiotherapy, gemcitabine-
capecitabine and FOLFIRINOX are expected by the end of 2020 and could clarify which 
strategy is most promising. It should be mentioned that also in the neoadjuvant setting, only 
well performing patients qualify for FOLFIRINOX based therapy.  
1.3.4. Palliative therapy 
The only treatment option for patients with distant metastases or locally advanced irresectable 
tumors is palliative care. For decades, 5-FU remained the only available chemotherapeutic 
agent in the metastatic setting. This changed in 1997, when 5-FU was compared with 
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gemcitabine (Burris et al., 1997). Although the survival extension was minimal (mOS 
gemcitabine 5.65 months vs. 5-FU 4.41 months), gemcitabine had less severe side effects. In 
2011 FOLFIRINOX proved to be superior over gemcitabine in the ACCORD-11 trial. 
FOLFIRINOX treated patients reached mOS of 11.1 months, while gemcitabine treated cohort 
reached only 6.8 months (Conroy et al., 2011). In the same year as the ACCORD-11 trial the 
MPACT trial compared the combination of gemcitabine/nab-paclitaxl versus gemcitabine 
monotherapy. The combination therapy elevated the mOS to 8.7 months from 6.6 months in the 
monotherapy group (Von Hoff et al., 2011).  
 1.3.5. Second line treatment 
Even with the recent advances in surgery, adjuvant and neoadjuvant therapy, most PDAC 
patients relapse. Around half the patients of the PRODIGE-4 trial later underwent second-line 
chemotherapy (Conroy et al., 2011). It has been shown that after initial gemcitabine therapy, 
the mixture of oxaliplatin, 5-FU and folinic acid offers a mOS of 5.9 months, while 5-FU and 
folinic acid alone reach a mOS of 3.3 months (Oettle et al., 2014). A 2016 published study 
showed that the combination therapy of nal-irinotecan, 5-FU and folinic acid offers similar 
mOS (6.1 months) as seen before with oxaliplatin, 5-FU and folinic acid (Wang-Gillam et al., 
2016). Phase III studies investigating second line treatment after initial 5-FU containing therapy 
are missing. Thus, it is currently advised to administer oxaliplatin or nal-irinotecan in 
combination with 5-FU and folinic acid after initial gemcitabine treatment and nab-paclitaxl 
with gemcitabine after initial 5-FU usage (Sohal et al., 2016; Sohal et al., 2020).  
An exemplary treatment algorithm summarizing current treatment options with expected 





Figure 2: Exemplary treatment algorithm summarizing current treatment options for PDAC.  Patients are 
stratified according to the stage of the tumor (resectable/borderline resectable/metastatic) and patient performance 
status (Eastern Cooperative Oncology Group (ECOG) score). Median survival in the blue fields has been added 
from the latest clinical data. Median survival in the red fields refers to first-line survival and is estimated from 
Neoptolemos et al.. Modified from (Neoptolemos et al., 2018).  
 
1.4. Novel therapeutic options 
Although regimens developed in recent years can markedly elevate overall survival, especially 
for resectable tumors, this comes at the cost of increased severe side effects. In addition, the 5-
year overall survival rate remains low at around 8-9%. Other treatment options are limited to 
small subpopulations of PDAC patients, and large phase III results are missing. Furthermore, 
current therapies for metastatic or relapsed patients barely increase the overall survival. This 
section discusses some of the novel therapeutic options that are currently being explored in the 
hope of significantly improving treatment options for PDAC patients. 
1.4.1. Targetability of patient specific mutations 
Although the mutational landscape of PDAC consists of only four main genes, very few of these 
genetic alterations offer druggable targets. This is different for the specific case of the 
KRASG12C mutation. It is found in 1.5% of PDAC patients and can be targeted with the small 
molecule KRAS inhibitor AMG 510 (Canon et al., 2019). Its use showed high efficacy in 
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murine xenograft models and also in a preliminary clinical evaluation of KRASG12C bearing 
non-small-cell lung cancer (NSCLC) patients. All patients demonstrated either stable disease 
or a partial response (Canon et al., 2019). However, these are only initial findings and more 
data need to be collected, as well as the assessment of its benefit in PDAC. Around 5% of 
PDAC patients carry loss-of-function mutations in the genes BRCA1 and BRCA2 (Holter et 
al., 2015). These genes are involved in homologous recombination repair, which is why this 
genetic anomaly proved to be sensitive towards inhibition of the enzyme poly ADP ribose 
polymerase (PARP) with the small molecule olaparib (Golan et al., 2019). PARP is 
indispensable for single-strand DNA repair and inhibition is therefore inducing apoptosis of the 
malignant cells. In a recent phase III trial, significantly increased progression-free survival was 
observed in a patient cohort that was previously sensitive to the DNA damage agent cisplatin 
(Golan et al., 2019). Nevertheless, the aforementioned therapies are still in an experimental 
phase, only showed elongation of progression free survival, and – most importantly – are only 
suitable for selected subpopulations of PDAC patients.  
1.4.2. Immunotherapy  
A new hope for patients with currently incurable neoplastic malignancies comes from 
immunotherapies. Immunotherapy is a relatively new field within oncological research. It 
gathered a lot of momentum in the last decade and peaked in the awarding of the 2018 Nobel 
Prize in Physiology or Medicine to James P. Allison and Tasuku Honjo for discovering a cancer 
therapy using immune-checkpoint regulation (Guo, 2018). Since the revelation of the pivotal 
roles of PD-1 and CTLA-4 (Ishida et al., 1992; Leach et al., 1996), blocking their function by 
antibodies has become a standard-of-care therapy for multiple indications, first and foremost in 
melanoma (Hodi et al., 2010; Gong et al., 2018). Immune checkpoint inhibition has also been 
investigated in the setting of pancreatic cancer but could not proof any meaningful benefit 
(Henriksen et al., 2019). A few reasons have been proposed for this. The development of PDAC 
comes along with a strong desmoplastic reaction of the tumor microenvironment (TME) (Henze 
et al., 2020). The TME of PDAC is very hostile towards T cells, the main profiteers of immune-
checkpoint inhibition. There are physical barriers, such as a hypovascularized stroma, 
preventing T cells from extravasating blood vessels as well as a dense extracellular matrix 
(ECM), averting effective migration (Henze et al., 2020; Hosein and Brekken, 2020). The 
stroma is nutrient poor and hypoxic. Even if a T cell reaches a tumor cell, it needs to recognize 
the tumor cell as malignant, which works via the presentation of mutated neoantigens through 
the MHC complex and their recognition by the T cell receptor. It has been shown that tumor 
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cells can downregulate MHC molecules and PDAC commonly shows a low mutational burden 
leading to a very limited number of neoantigens (Chen et al., 2020; Yamamoto et al., 2020). In 
addition, the TME is filled with immunosuppressive cells, such as regulatory T cells and 
myeloid-derived suppressor cells, preventing T cells from switching to an activated state 
(Hosein and Brekken, 2020). One approach to overcome these hurdles is the application of 
chimeric antigen receptor (CAR) engineered T cells. Thereby, the T cells are modified to act 
independent of the MHC/TCR pathway, can be engineered to excrete ECM digestive enzymes 
(Caruana et al., 2015), can be altered to convert suppressive TME signaling into an activating 
one and most important (Leen et al., 2014; Mohammed et al., 2017), are a “living drug” making 
them more persistent and active than small molecules. However, so far CAR T cells proved 
efficacy mostly in hematologic tumors such as B cell malignancies (Schmidts and Maus, 2018). 
The reasons for this are thought to be based on two major characteristics: 1. The tumor cells are 
located in organs well accessible for the CAR T cells like blood and bone marrow and 2. Tumor 
targets such as CD19 or CD20 are widely expressed on the tumor cells and harbor very limited 
on-target off-tumor toxicities (Tokarew et al., 2019). 
1.5. Chimeric Antigen Receptors 
CARs render T cell activation independent of the MHC/TCR signaling axis by providing a 
direct link between binding to a cell surface molecule on the target cell and inducing TCR-like 
signaling. Their modular blueprint consists of four major building blocks: In the extracellular 
compartment, a CAR comprises an antigen binding domain and a spacer (also referred to as 
hinge) domain. The spacer domain is followed by a membrane-spanning transmembrane 
domain and one or more intracellular signal transduction domains (Miliotou and Papadopoulou, 
2018).  
1.5.1. CAR design: Antigen binding domain 
Grafting new specificity onto a T cell was pioneered in 1987 by Kuwana et al.. They engineered 
a new immunoglobulin-derived variable region onto T-cell receptor constant regions (Kuwana 
et al., 1987). Two years later, this method was refined by Gross et al., who were the first to fuse 
antibody derived binding domains onto the T-cell receptor (Fig. 3)(Gross et al., 1989). 
Although, this modified TCR was able to stimulate the T cell, this approach had some 
insufficiencies. Cloning was laborious and surface expression inefficient. Ultimately, the whole 
CD3:TCR complex had to form properly to convey activation. This led to the development of 
a new single polypeptide chain format (Fig.3), incorporating a single-chain variable fragment 
(scFv) as antigen binding domain (Eshhar et al., 1993). The use of antibody derived binding 
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domains also has practical implications: They offer high affinity binding and target candidates, 
which have been discovered using antibodies, can be targeted with an scFv derived from the 
very same antibody, streamlining the subsequent CAR design. Thus, most of the antigen 
binding domains in use today have been derived from the variable heavy (Vh) and variable light 
(Vl) chains of monoclonal antibodies connected with a flexible linker (Gacerez et al., 2016). 
The scFv brings along a set of properties influencing CAR behavior beyond sole antigen 
recognition. The affinity of an scFv needs to surpass a certain threshold to be able to activate 
the T cell upon antigen binding, but too high affinity can lead to activation induced cell death 
(AICD)(Watanabe et al., 2014; Lynn et al., 2016; Dwivedi et al., 2018). Also long-term 
persistence seems to be improved when using low to medium affinity scFvs (Ghorashian et al., 
2019). Interestingly, affinity fine-tuning can also be utilized for engineering CARs to spare 
normal tissues but preserve antitumor activity by inducing T cell activation only in case of a 
high level of target expression on the cell surface (Caruso et al., 2015). 
1.5.2. CAR design: Spacer domain 
The antigen binding domain is followed by a spacer domain, sometimes also referred to as hinge 
(Cartellieri et al., 2010). Originally, the spacer domain was thought as a structural element, 
which would help the antigen binding domain to reach over the dense glycocalyx of  T cells 
(Moritz and Groner, 1995). To this end, a variation of different spacer domains have been 
designed, mainly consisting of immunoglobulin-like domains (Ig) crystallizable fragments (Fc) 
from antibodies (Hombach et al., 1998; Weijtens et al., 1998; Cooper et al., 2003). Later, 
domains derived from CD8α, CD28, NKG2D, TCRβ, IgD, IgG1 and IgG4 have been added 
(Darcy et al., 1998; Eshhar et al., 2001; Niederman et al., 2002; Zhang et al., 2005; Morgenroth 
et al., 2007; Barber et al., 2008; Wilkie et al., 2008; Hombach et al., 2010; Jonnalagadda et al., 
2015). Notably, comparative studies between spacers and especially among distinct spacer 
classes are rare in the current literature. An important study providing insight on the influence 
of CAR spacers was conducted by Patel and colleagues (Patel et al., 1999). They proved that 
differing spacers in otherwise identical CAR designs lead to differences in CAR stability, 
cytokine secretion and cytotoxic activity. Later, studies elaborated that CAR T cell activity was 
not only bound to attributes of the original molecule, but also depended on the position of the 
respective target epitope. Long CAR spacers evolve higher efficiencies when targeted towards 
membrane proximal epitopes. On the other hand, short spacers proved higher functionality in 
the context of membrane distal epitopes (Guest et al., 2005; James et al., 2008; Haso et al., 
2013; Hudecek et al., 2013; Krenciute et al., 2016). Thus, the choice of the optimal spacer 
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domain needs to be considered wisely. Another point to consider when choosing a spacer 
domain is the different behavior of some spacers in vitro and in vivo. Some spacers were found 
to exhibit unspecific Fc-Receptor (FcR) binding capacity in murine models, leading to AICD 
and their accumulation in the lung (Hombach et al., 2010; Hudecek et al., 2015; Jonnalagadda 
et al., 2015). 
1.5.3. CAR design: Transmembrane domain 
The transmembrane domain anchors the CAR to the cell surface and connects the extracellular 
domains to the intracellular domains. Traditionally, this domain is based on peptide sequences 
from CD3ζ, CD28 or CD8α. Despite early research revealing the importance of the CD3ζ 
transmembrane domain for dimerization with the natural CD3ζ  frame work and improvement 
of T cell activation (Romeo et al., 1992), research into its importance in the overall CAR 
functionality was long neglected. 18 years later, Bridgeman et al. showed that the optimal 
antigen response of CD3ζ-based CARs depends on dimerization with the endogenous CD3 
complex (Bridgeman et al., 2010). Not only can the transmembrane domain facilitate 
dimerization but also influences the molecule’s stability. It has been reported that CD3ζ 
incorporating CARs are less stable than CD28 transmembrane harboring CARs (Dotti et al., 
2014). In the case of an ICOS-based transmembrane domain, it was found that this domains 
influences the in vivo phenotype of T cells (Guedan et al., 2018). Also cytokine release is 
dependent on membrane spanning CAR configuration (Hudecek et al., 2015). Hence, more 
investigations are needed to better predict CAR functionality in dependence of the 
transmembrane domain. 
1.5.4. CAR design: Intracellular domain  
The signaling region in the initial CAR constructs was only comprised of the CD3ζ cytoplasmic 
domain harboring three immunoreceptor tyrosine-based activating motifs (ITAMs). These 
motifs are phosphorylated in response to antigen binding, which represents the first step in the 
subsequent signaling cascade resulting in T cell activation (Bezbradica and Medzhitov, 2012). 
CARs comprising only the CD3ζ signaling domain are known as first-generation CARs. Albeit 
activation and in vitro functionality can be achieved by one CD3ζ domain alone (Haynes et al., 
2001), the anti-tumor response of first generation CARs was very limited (Brocker and 
Karjalainen, 1998; Brocker, 2000; Brentjens et al., 2007). Later it became apparent that T cells 
require a second – co-stimulatory – signal for full functionality (Fig. 3). One example is CD28 
being co-stimulated by B7 presenting cells (Lenschow et al., 1996). As it cannot be expected to 
find B7 on tumor cells as it is a molecule commonly found on antigen presenting cells, the next 
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step was to incorporate the co-stimulus within the CAR framework.  Once included, IL-2 
production and cell expansion is superior over first-generation CARs (Finney et al., 1998; 
Maher et al., 2002). Another finding of both studies influencing CAR design until today was 
the importance of the orientation and positioning of both stimulating domains. Only a 
membrane proximal co-stimulus and membrane distal CD3ζ configuration is able to convey a 
sufficient stimulus. Nowadays, most intensively investigated co-stimulatory domains are either 
derived from 4-1BB or CD28 (Gacerez et al., 2016). A myriad of other co-stimulating domains 
has been investigated, including OX40, ICOS, CD27, KIR2DS2, MYD88 and CD40 (Hombach 
et al., 2012; Song and Powell, 2012; Duong et al., 2013; Hombach et al., 2013; Guedan et al., 
2014; Wang et al., 2015; Mata et al., 2017). It was elucidated that CD28 co-stimulus drives 
CAR T cells into an effector memory (TEM) phenotype using aerobic glycolysis, while 4-1BB 
containing CARs differentiate into central memory T cells (TCM) and rather use oxidative 
metabolism (Kawalekar et al., 2016). The influence of other co-stimulating domains for T cell 
activation, differentiation and persistence continues to be a field of active research. 
In 2007, CARs of the third generation were introduced (Fig. 3). In the pursuit of better efficacy, 
Wang et al. combined CD28 and 4-1BB co-stimulatory domains resulting in higher 
cytotoxicity, cytokine release and proliferation (Wang et al., 2007). In the following years, CAR 
T cells proved to be extremely effective in certain settings, with response rates in leukemia from 
57%- 93% and in lymphoma from 25%- 100%, not uncommonly as a last line therapy (June 
and Sadelain, 2018). The logical consequence was the first approval of commercial CAR T cell 
products for B cell malignancies (Zheng et al., 2018). This story of success led to the expansion 
of CAR T cell research targeting other tumor entities. As the range of applications increased, 
so too did the demands on CAR T cell therapies. In response to the multifactorial hurdles CAR 
T cells are facing for the different fields of application, CARs of the fourth and fifth generation 
have been developed (Fig. 3)(Tokarew et al., 2019). Both generations are based on second 
generation backbones. Fourth generation CARs constitutively or inducibly produce cytokines, 
such as IL-12, IL-15 and IL-18 (Hoyos et al., 2010; Pegram et al., 2012; Chmielewski and 
Abken, 2017). CARs of the fifth generation contain an IL-2 receptor β-chain, which comprises 
a binding moiety for STAT3. This leads to a triple pathway activation: 1.) TCR signaling is 
triggered by CD3ζ, 2.) co-stimulation by CD28 and 3.) cytokine signaling via the JAK-
STAT3/5 pathway (Kagoya et al., 2018). However, future trials have to prove their superiority 




Figure 3: Overview of CAR generations.  First attempts to graft novel specificity onto T cells exchanged variable 
regions of the TCR alpha and beta chains with novel binding moieties (here variable chains from antibodies). From 
the first generation onwards, CARs consisted of only one polypeptide chain. Binding is usually conveyed by 
antibody derived single chain variable fragments (scFvs). A spacer (SP) connects the binding moiety with the 
transmembrane domain (TM). The intracellular domains differ among the generations. First generation CARs 
comprised only a signaling domain from CD3ζ containing three immunoreceptor tyrosine-based activating motifs 
(ITAMs/red boxes). These motifs are phosphorylated in response to antigen recognition, starting the subsequent 
signaling cascade for T cell activation. The second generation includes a co-stimulating domain between TM and 
CD3ζ, normally derived from CD28 or 4-1BB and contains one ITAM motif. CARs of the third generation are 
characterized by two co-stimulating domains. CARs of the fourth generation are coupled to chemokine production. 
Here, an inducer for IL-12 is depicted. Fifth generation CARs contain a cytokine receptor domain leading to multi-
pathway cascades. Cytotoxic potential, released cytokines and persistence increased from generation one to three, 
whereas from generation four onwards multifunctionality increased. Modified from (Tokarew et al., 2019) and 
(Wu et al., 2020). 
 
1.6. CAR T cell developments in the field of PDAC 
CAR T cells brought new hope for patients formerly believed to lack therapeutic options. This 
unparalleled success in the field of hematologic malignancies sparked hope to also open up 
novel therapeutic options in the field of pancreatic cancer.  
1.6.1. CAR T cells for PDAC: Clinical experience 
One of the most crucial factor for success of CAR T cell based therapies is the knowledge about 
safe and efficient targets present on the tumor cells. Suggested targets that recently have been, 
currently are, or in near future will be investigated in the PDAC setting, include but are not 
limited to mesothelin (MSLN; NCT03323944, NCT03497819, NCT03638193, 
NCT01897415), carcinoembryonic antigen (CEA; NCT03818165, NCT02850536, 
NCT02416466, NCT04037241, NCT03682744), CD133 (NCT02541370), CD70 
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(NCT02830724), Claudin 18.2 (NCT03159819), epithelial cell adhesion molecule (EpCAM; 
NCT03013712), human epidermal growth factor receptor 2 (HER2; NCT02713984) mucin 1 
(MUC1; NCT02587689) and prostate stem cell antigen (PSCA; NCT02744287).  
CAR T cells harbor an enormous cytotoxic potential. All the CAR targets listed above are 
overexpressed in cancer cells but are also expressed on normal tissues, implying the risk of 
harming significant parts of healthy tissues. This effect is known as on-target/off-tumor toxicity. 
In the instance of B cell malignancy therapies targeting pan-B cell markers such as CD19 or 
CD20, this is acceptable, as B cell aplasia is treatable. For solid tumors, and PDAC targets in 
particular, less tolerable side effects have been reported. An administration of CAR T cells 
specific for HER2 led to fatal systemic organ failure and massive cytokine release (Morgan et 
al., 2010). This was attributed to HER2 expression in the lung epithelium. Maximum T cell 
expansion coincided with respiratory toxicities during a trial of CEA specific CAR T cells, 
which were also thought to be linked to CEA expression in the lung (Thistlethwaite et al., 2017). 
On the other hand, encouraging results could be achieved in a trial targeting CD133. Two 
patients experienced partial remission and only grade II toxicities, attributed to CD133 
expression on hematopoietic stem cells (Wang et al., 2018). To further decrease the risk of on-
target/off-tumor toxicity, Beatty and colleagues chose a transient MSLN CAR expression 
method by transfecting T cells with CAR mRNA before infusion. In a phase I study, they 
observed progression free survival in two patients for up to five months and shrinkage of a liver 
lesion in a third patient. No adverse events were reported (Beatty et al., 2018). These examples 
have risen hope for PDAC patients indicating that indeed this disease can respond to CAR T 
cell based therapies. On the other hand it again taught the research community the importance 
of identifying novel target candidates including a thorough safety assessment and further 




1.7. Aims of the study 
PDAC is particular challenging for modern oncology. Current treatment options mainly aim at 
extending the remaining lifespan as a curative intervention is unlikely. Although encouraging 
results could be achieved in recent years, no breakthrough developments are to be expected in 
the near future from conventional therapy approaches. CAR T cells are a powerful new option 
for cancer therapy. While remarkable results have been accomplished in the setting of 
hematologic malignancies, several hurdles still need to be overcome for their application in the 
treatment of PDAC.  
1.7.1. Identification of specific and safe target candidates 
A critical stage during CAR T cell development is the choice of the right target antigen. Until 
today, a comprehensive assessment comparing target candidates for their specificity towards 
PDAC cells and studies evaluating their off-tumor expression are missing. This neglect of the 
safety aspects in the past already have led to fatal outcomes and severe side effects. Hence, one 
aim of this study was the identification of novel target candidates with high tumor specificity 
and low expression in healthy tissues. The specificity to tumor cells was to be investigated using 
an antibody based target discovery approach. This enabled an experimental assessment of tumor 
and healthy tissue expression and facilitated a simplified subsequent CAR design due to the 
direct transfer option of existing scFvs. This part of the study is investigated in “Chapter I - 
CD318, TSPAN8 and CD66c resemble novel candidates for CAR T cell based immunotherapy 
of pancreatic adenocarcinoma”.     
1.7.2. Generation and evaluation of target specific CAR T cells 
The optimal CAR configuration depends on multiple parameters, one important being the 
location of the epitope. Long spacers more efficiently target membrane proximal epitopes and 
vice versa. As the exact location of the target epitope is not known in most of the cases, CAR 
libraries have to be generated and screened. In addition, in vitro and in vivo performance of 
CARs may vary based on CAR design, affinity, target expression among others and have to be 
tested empirically. Thus, the second objective of this study was the identification of the most 
efficient CAR design for the newly identified target candidates. This issue is further addressed 
in “Chapter I - CD318, TSPAN8 and CD66c resemble novel candidates for CAR T cell based 
immunotherapy of pancreatic adenocarcinoma”.     
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1.7.3. Development of a novel class of long spacer domains 
It is known that spacer length and structural attributes significantly influence CAR activity. 
However, comparative studies among spacer classes are sparse. In addition, IgG-based long 
spacer seem to have a risk of unspecific binding within murine models, leading to inferior 
functionality and contradicting results in vitro and in vivo. To overcome the inherent problems 
of long IgG-based spacer, the last objective of this study was the development of a novel class 
of CAR spacer, with similar attributes as the IgG class, but lacking their natural unspecific 
binding moieties. The generation and evaluation of this novel spacer class is outlined in 
“Chapter II - A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells 
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Figures, sub-figures, tables and experiments 
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Writing 
The manuscript was written by myself with support from Dr. Olaf Hardt and input from all co-
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The manuscript was initially conceptualized by me and shared first author Janina Henze and 
the design of the study was further specified in association with Dr. Rita Pfeifer, Dr. Olaf Hardt, 
Dr. Wa’el Al Rawashdeh and Dr. Ian C. D. Johnston. Dr. Rita Pfeifer designed the novel class 
of Siglec spacers and shared her results using the spacers in a CD20 based model, while Janina 
Henze and Dr. Wa’el Al Rawashdeh shared their results from the IgG1-based spacer trials, also 
in a CD20 model. I recognized the pattern of activation in dependence to the target length and 
designed the experiments on the basis of targets with different epitope distance to the cell 
membrane. This enabled us to identify the Siglec-4 based CAR as highly efficient on membrane 
proximal epitopes with advantageous T cell and cytokine release phenotype. Subsequently, we 
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One Sentence Summary  
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A major roadblock prohibiting effective cellular immunotherapy of pancreatic ductal 
adenocarcinoma (PDAC) is the lack of suitable tumor-specific antigens. To address this 
challenge, we combined flow cytometry screenings, bioinformatic expression analyses and a 
newly developed cyclic immunofluorescence platform. We identified CLA, CD66c, CD318 
and TSPAN8 as novel target candidates among 371 antigens and generated 32 CARs specific 
for these molecules. CAR T cell activity was evaluated in vitro based on target cell lysis, T cell 
activation and cytokine release. Promising constructs were evaluated in vivo. CAR T cells 
specific for CD66c, CD318 and TSPAN8 demonstrated efficacies ranging from stabilized 
disease to complete tumor eradication with CD318 being the most promising candidate for a 
clinical translation based on functionality and its predicted safety profile. This study reveals 
novel target candidates for CAR T cell based immunotherapy of PDAC together with a 
functional set of CAR constructs specific for these molecules.  
Introduction  
Pancreatic cancer is a devastating disease. The 5-year overall survival rates have merely 
changed for the past decades and it is currently the fourth leading cause of cancer related deaths 
in Western countries (1,2). Surgery still is the only potentially curative treatment, but only 
around 20% of patients show a resectable disease stage at diagnosis (3). Median overall survival 
with state-of-the-art treatment ranges from 26 month for patients with resectable disease to less 
than six months when already metastatic (4). Thus, there is an unmet need for new therapeutic 
options. A new and promising therapeutic approach are chimeric antigen receptor (CAR) T 
cells. CAR T cells showed unprecedented efficacies in the treatment of B cell malignancies 
(5,6). They typically rely on Pan-B cell antigens such as CD19 or CD20 and do not discriminate 
between healthy and tumor cells. As a consequence, all B cells are depleted, which is regarded 
as an acceptable side effect since it is otherwise well tolerated (7). This is not the case for almost 
all target antigens in solid tumors until today and remains one of the central problems of solid 
tumor CAR T cell therapies. Prominent candidates among the targets which are currently under 
investigation in clinical trials for pancreatic cancer are carcinoembryonic antigen (CEA), 
human epidermal growth factor receptor 2 (HER2), mucin 1 (MUC1), prostate stem cell antigen 
(PSCA), prominin 1 (PROM1), epidermal growth factor receptor (EGFR) and mesothelin 
(MSN) (8). These target candidates all have in common their shared expression on malignant 
and healthy tissues and toxicities in humans were already reported for HER2 and CEA. While 
administration of HER2 specific CAR T cells ended fatal for the patient (9) the use of CAR T 
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cells against CEA caused only mild toxicities but also very limited efficacy (10,11). These 
examples underline how important the aspect of safety is, which in case of CAR T cells comes 
with tumor specificity and off-tumor expression in dispensable cell types only. 
Until today, a broad and systematic target antigen screen for CAR T cell therapy of pancreatic 
cancer that compares the specificity of a multitude of target candidates and their off-tumor 
expression has not been reported. Likewise, empirical studies needed to determine an optimal 
CAR design on suitable targets for this disease are also scarce (12).  
Hence, we aimed to close this gap and present here a systematic approach for CAR target 
screening that first narrowed down the field of target candidates from 371 to 50 by flow 
cytometric analysis of 17 pancreatic cancer patient derived xenograft (PDX) models. We 
investigated further the RNA and protein expression profiles of these target candidates which 
are available in public online data banks. We ranked the candidates in dependence of their 
expression in different healthy tissues and cell types. In addition, we examined the expression 
of a multitude of these target candidates within primary pancreatic cancer tissues from patients 
using a newly developed cyclic immunofluorescence imaging platform. This new and powerful 
technique enabled us to survey expression profiles of several dozens of antigens on the very 
same tissue section. We finally verified these results using flow cytometry on seven additional 
primary PDACs. Based on these results, we designed 32 CARs specific for the four most 
promising target candidates, CLA, CD66c, TSPAN8, and CD318 with varying spacer lengths 
and scFv orientations. We empirically evaluated the CAR constructs in terms of cytotoxicity, 
cytokine release and cell phenotype profile. CAR constructs that performed best in vitro were 
then examined in two independent preclinical mouse xenograft models and evaluated for their 
expression on healthy tissues by cyclic immune fluorescence and flow cytometry resulting in 
promising candidates for future clinical trials. 
Results  
Identification of novel PDAC cell surface target candidates for CAR T cell based 
immunotherapy  
As pancreatic ductal adenocarcinoma (PDAC) attributes to around 85% of all pancreatic cancer 
cases, we decided to use PDX models of PDAC for initial candidate identification due to their 
good availability and proven predictivity for the disease (13). A scheme of the workflow for 
identification of novel target candidates applied in this study is depicted in Fig. S1. Overall, we 
analyzed 17 independent PDX models representing 15 different mutational backgrounds. 
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Initially, we screened two PDX models representative of PDAC concerning histology, 
mutational profile and characteristic response to standard-of-care drugs (Charles River personal 
communication) using a commercially available antibody array containing antibodies specific 
for 371 surface antigens, including antigens already under clinical investigation for CAR T cell 
based treatment of PDAC, such as HER2, MUC1, PROM1 and CEA. We found 105 antigens 
to be expressed on more than 10% of the PDX cells on at least one of the PDX. We then used 
antibodies specific for these 105 antigens and measured their expression on two additional 
representative PDX models followed by a manual exclusion of non-suitable target candidates, 
such as HLA molecules which were present in the pre-set screening plates. We measured the 
remaining 50 surface antigens, which were expressed in at least 20% of all tumor cells of at 
least three out of four PDX models, on 13 more xenografts (Fig. 1a, Fig. S2). Remarkably, 
MUC1 and HER2 did not match these criteria. A family of proteins that was expressed on many 
tumor cells of the PDX models was the one of the tetraspanins. Prominently expressed members 
were CD9, CD63, CD82 and CD151. Another family that showed expression on many tumor 
cells throughout the different PDX models was the CEA family. Its members CEACAM1, 
CEACAM3, CEACAM5 and CEACAM6 could all be recognized by the pan-reactive 
CD66acde antibody. However, the expression pattern of CD66acde was paralleled by the 
expression of CD66c alone and based on the higher specificity of the single molecule binder 
we chose this one for further evaluation. Unexpectedly, we found the cutaneous lymphocyte 
antigen (CLA) expressed on all but one xenograft. CLA is described as a binding epitope of the 
antibody clone HECA 452 and includes a sialyl-Lewis X glycan structure (14,15). So far, CLA 
was only observed to be expressed on subsets of leukocytes (14,16-19). This is in two ways an 
interesting finding: it was never described before to be expressed on pancreatic cancer cells and 
was so far only reported to be expressed on sub sets of certain cell types, which could mean no 
essential tissues may be harmed when targeted by CAR T cells. 
CD66c, CD318, TSPAN8 and CLA exhibited restricted off-tumor expression in human 
tissues  
Next, we prioritized the 50 surface structures from our antibody screen with respect to their off-
tumor expression. We assigned the corresponding genes to their respective antigens. For some 
instances multiple genes had to be assigned to a single antibody. For example CD66acde 
represents CEACAM1, CEACAM3, CEACAM5 and CEACAM6. In cases like this, each gene 
was investigated independently. In case an antibody was specific for a glycostructure we 
assigned the respective backbone protein to it (for example CLA can be a glycostructure on 
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SELPLG (14)), if possible. Subsequently, we extracted RNA and protein expression data of the 
assigned genes from the following data sources: Human Protein Atlas (20), ProteomicsDB (21), 
Human Proteome Map (22) and GTEx. Next, we defined rankings independently for each 
dataset. Detailed information about the ranking procedure can be found in the Materials and 
Methods part. In brief, genes of each data set were ranked by the total number of tissues/cell 
types it was expressed in as well as their overall expression levels. Subsequently, we calculated 
a rank sum that mirrors the overall expression throughout all data sources (Tab. S1, Fig. S3). 
The final rank was then calculated based on the quotient of the rank sum of the target candidate 
divided by the number of data sources it was found in. As a consequence, target genes expressed 
in a low number of tissues were prioritized as they are expected to cause lower potential off-
tumor effects.  
All four members of the CEA family that are bound by the CD66acde antibody exhibited only 
restricted expression over several tissues (Tab. S1, Fig. S3). Other target candidates that 
appeared top ranked were the Rh blood group polypeptides RHD and RHCE (CD240DCE), the 
C-C chemokine receptor type 5 (CCR5, CD195), CXC chemokine receptor 3 (CXCR3, CD183) 
or CUB domain-containing protein 1 (CDCP1, CD318). Remarkably, from the five tetraspanins 
found prominently expressed on the xenografts only TSPAN8 remained in the 20 top ranked 
candidates, showing that TSPAN8 has the most restricted expression profile of them. 
Furthermore, we found SELPLG as the protein backbone of CLA also belonging to the 20 best 
ranked candidates.  
In addition, we included MSN and EGFR into our bioinformatic analysis as they were not 
present in the antibody library, whereas other candidates currently evaluated in clinical trials, 
such as CEA, HER2, CD133 and MUC1 were included in our screen, showing rankings similar 
to our subsequent target candidates (Tab. S1, Fig. S3). As an independent validation of our 
bioinformatics based strategy, we applied an algorithm according to the one developed by Perna 
et al. (23) resulting in a comparable prioritization (Tab. S1). 
Validation of CD66c, CD318, TSPAN8 and CLA expression and specificity  
An important information, that is lost during the processing of samples for RNA or protein 
expression analysis is the spatial distribution of target candidate expression within the tissue. 
Strong mRNA expression values derived from small populations of cells that may be acceptable 
with respect to toxicities are intermingled with the rest and turn suitable targets to false 
negatives. To overcome these problems and to gain a better understanding of the target 
candidate expression in primary PDACs in situ, we used a newly developed cyclic 
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immunofluorescence imaging platform. This system operates by iterative fluorescence staining, 
imaging and signal erasure, enabling the operator to identify the expression of dozens of targets 
on the very same tissue section. We performed two runs of cyclic immunofluorescence imaging 
on two different PDAC tumor tissues with 107 and 98 markers, respectively (Tab. S2). These 
markers were a selection of the ones used on the PDX models plus markers to dissect known 
cell lineages. Our observations were centered on identifying candidates showing colocalization 
with tumor cells and no or low expression on non-tumor cells. Target candidates that were 
ranked promising through bioinformatics and showed specific expression on tumor cells from 
patients were CLA, TSPAN8, CD318 and CD66c (Fig. 1b, Tab. S1, Fig. S3). Other candidates 
such as CD240DCE, CD195 and CD183, which were ranked well before exhibited strong 
expression on non-tumor cells. Some candidates appeared to be specific to the tumor cells, 
although they did not belong to the group of high ranked targets, such as CD49c, CD73, CD104 
and CD142 suggesting a generic epithelial reactivity (Fig. 1b). CD51, CD59 and CD107a had 
low bioinformatic ranks and presented massive expression offside of tumor cells, nicely 
confirming the value of this approach. 
These findings led to the decision to further verify the specificity of CD49c, CD66c, CD73, 
CD104, CD142, CD318, CLA and TSPAN8 on primary pancreatic tumor cells using flow 
cytometry. We dissociated seven human PDAC specimens and gated either on tumor cells 
(EpCAM+), leukocytes (CD45+) or other cells (double negative). It was shown that these eight 
candidates indeed showed a significant enrichment of expression on tumor cells (Fig. 1c, Fig. 
S4). We decided to continue with the generation of CARs specific for CLA, CD66c, CD318 
and TSPAN8, since the bioinformatical rankings indicated a higher health threat for CD49c, 







Fig. 1: Identification of novel PDAC CAR target candidates. (a) Top 50 antigens expressed on the cell surface 
of PDAC PDX models as determined by flow cytometry based screening of a 371 monoclonal antibody panel. (b) 
Selection of 15 cyclic immunofluorescence images of a representative human PDAC tissue to evaluate co-
expression of the marker of interest (MOI) with cytokeratin-positive tumor cells. (c) Flow cytometric analysis of 
expression for eight target candidates on primary human PDAC samples. Data represent mean ± s.e.m. (n=7, ****P 
< 0.0001 determined through two-way ANOVA with Tukey’s test). 
CLA specific CARs are dysfunctional, while CARs specific for CD66c, CD318 and TSPAN8 
induce potent activation, cytokine release and antitumor efficacy in vitro  
After identification of the four target candidates CLA, CD66c, CD318 and TSPAN8, we 
designed a CAR library with varying spacer lengths (XS, S, M and L) and scFv orientations 
(Vh-Vl and Vl-Vh) (Fig. 2a). It has been shown that these elements are critical for CAR function 
(12,24). All CARs shared a second generation design with CD3ζ and 4-1BB as stimulatory 
domains and a CD8α transmembrane domain. The CAR sequence was connected to the 
sequence of the extracellular domain of the Low-affinity nerve growth factor receptor (LNGFR) 
via a P2A site, to be used as a reporter protein. In total, eight CAR constructs with differing 
spacer lengths and varying scFv orientations were generated for each candidate.  
Following the design and cloning of the CAR containing plasmids, the general ability of the 
CAR constructs to be expressed and localized to the cell surface was assessed in transfected 
HEK293T cells (Fig. S5). The majority of constructs displayed LNGFR expression, indicating 
a functional CAR cassette. In contrast, the anti-Fab staining differed greatly among spacer 
lengths and scFv specificities (Fig. S5). Possible explanations could be a decreased stability as 
compared to LNGFR, suboptimal folding or cell surface localization characteristics of the 
artificial sequences that lead to an early intracellular degradation or sub-optimal binding of the 
polyclonal anti-mouse Fab. Most strikingly, anti-Fab staining of most of the M sized CARs 
showed substantial mal-expression. These findings reasoned us to exclude M sized CARs from 
further assessments.  
Following this, we set up an in vitro co-culture system to validate functionality of the remaining 
CARs. We generated GFP-Luciferin positive PDAC cell lines from established AsPC1 and 
BxPC3 PDAC lines as well as one cell line we derived directly from one of the primary tissues 
(PanCa0201). We co-cultured the target cell lines with CAR T cells in effector-to-target (E:T) 
ratios of 5:1, 2:1 and 1:1 over 6 days. We measured cytotoxicity as a function of decrease in 
viable target cell confluence. Samples of the supernatant were taken after 2 days of co-culture 
for cytokine release measurements and T cell activation/exhaustion marker expression was 
measured after 2 or 6 days. We considered GM-CSF, IL-2, TNF-α and INF-γ as the cytokines 
which have the highest value in terms of CAR T cell activity. The examined T cell markers 
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were PD-1, LAG-3, 4-1BB, TIM-3 and LAG-3/4-1BB co-expression. To ensure inter-
experiment comparability, we normalized the values to the highest of each assay. All CAR T 
cells were evaluated for unspecific activation and induction of tonic signaling in a co-culture 
with HEK293T cells, not expressing any of the target antigens (Fig. S6). Furthermore, general 
activation ability was tested stimulation T cells with PMA/Ionomycin (Fig. S6b, Tab. S3).  
All anti-CLA CARs performed much worse as compared to their counterparts for the other 
antigens (Tab S3, Fig. S7a). They displayed only weak killing and almost no cytokine release 
or marker upregulation. We think the cause of this was CLA to be a T cell self-antigen 
upregulated upon activation (Fig. S8). As shown above, the expression levels of CLA specific 
CARs in HEK293T cells were very low. This in combination with self-antigenicity may lead 
to binding of CAR and target already intracellular and in consequence to degradation of this 
complex. For CD66c CARs the S and XS spacer performed better in both scFv orientations as 
compared to the L spacer CARs. The Vl-Vh scFv orientation performed superior to the Vh-Vl 
orientation. The CD318 CARs featured similar behavior, with the XS and S spacers being 
superior to the longer L spacer. For CD318 the Vh-Vl conformation appeared to be more 
functional. These findings were contrasted by the CARs specific for TSPAN8, where the long 
spacer exhibited better cytotoxicity. The results of all in vitro functionality assays can be found 
in Tab. S3.  
Subsequently, we directly compared the best performing CARs based on the highest values of 
cytotoxicity, cytokine release and marker upregulation (Fig. 2b, Tab. S4). We chose the XS and 
S CARs in the Vl-Vh orientation for CD66c, the XS and S CARs in the Vh-Vl orientation for 
CD318, and the S and L spacer CARs in the Vh-Vl conformation as well as the Vl-Vh L spacer 
CAR for TSPAN8. In this direct comparison, the CD66c S spacer CAR outperformed the XS 
spacer CAR. Both CD318 CARs showed fast and efficient target cell killing with almost 
complete lysis using BxPC3 and the fastest kinetic using AsPC1 cells (Fig. 2c,d, Fig. S7b,c). A 
slight difference in performance only appeared based on cytokine release and activation marker 
upregulation. The XS spacer released less cytokines but exhibited improved activation marker 
upregulation. All other CARs showed cell lysis between 40% to 60% within the first 48 h 
following an outgrowth control until 160 h (Fig. 2c, Fig. S7b). The highest activation of 
TSPAN8 specific CARs showed the S spacer in Vh-Vl orientation (Fig 2b). As a consequence, 
we chose to evaluate the CAR constructs CD66c S Vl-Vh, CD318 XS Vh-Vl , TSPAN8 S and L  




Fig. 2: Generation of target candidate specific CAR constructs and evaluation of in vitro functionality. (a) 
Scheme of the generation of our CAR library. The combination of four backbones differing in spacer length with 
two scFv orientations and four target candidate specificities resulted in 32 constructs. (b) Average relative target 
cell killing, cytokine release, marker upregulation and overall performance (displayed as circle size) of the selected 
best performing CARs from the initial screening assays (y axis). The number of replicates is indicated in 
parentheses behind the construct name. (First value = n of killing assays, second value = n of cytokine release 
assays, third value = n of marker upregulation measurements). (c) Representative result for the kinetics of BxPC3 
target cell killing by the selected CAR constructs. (d) Representative results showing cytokine release and 
activation marker expression patterns upon co-culture with BxPC3 target cells. Shown are the means ± s.e.m. 
(n=2). Activation marker expression was measured at end point of cytotoxicity assay, cytokine release patterns 
were measured after 48 h. 
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CAR T cells specific for the novel target candidates exhibit potent anti-tumor responses in 
vivo  
To evaluate the most promising CAR candidates in a preclinical setting, we engrafted Luc+ 
AsPC1 cells subcutaneously in NSG mice. Tumor growth kinetics were evaluated by caliper 
and bioluminescence (BLI) measurements (Fig. 3a). After the first tumors reached a size of 
25mm², we injected 5x106 CAR T cells or untransduced T cells intravenously. Mock T cells 
exhibited no therapeutic benefit over the untreated group (Fig. S9a). All mice treated with Mock 
T cells were sacrificed latest 12 days post T cell injection due to appearance of ulceration in 
tumors (Fig. S9b). Remarkably, all tumors irrespective of the treatment grew in terms of size 
until 9 days post T cell injection, although for some animals the BLI signal decreased already 
after six days (Fig. 3b,c-d). We could verify that this drop in BLI signal and increase in size 
was caused by tumor cell lysis initiated trough massive CAR T cell and macrophage infiltration 
(Fig. 4c). Complete and fast tumor eradication was observed in the CD318 XS CAR treated 
group. The TSPAN8 S CAR showed a slower therapeutic kinetic but achieved tumor clearance 
in three mice and almost complete clearance in one mouse. The TSPAN8 L CAR exhibited 
heterogeneous response with three complete responders and two mice showing stable tumor 
burden. The CD66c S spacer performed poorly in comparison but still stabilized the tumor 
burden in all animals (Fig. 3b,c). Flow cytometric analysis of spleen CAR T cells revealed that 
the groups CD318 XS and TSPAN8 S had the highest CAR T cell counts at the end of the 
experiment correlating with the highest anti-tumor activity (Fig. 4a). In addition, the two low-
responder mice showed the lowest CAR T cell count inside the TSPAN8 L group. However, 
the comparable cell counts of the CD66c group showed that the CAR T cell number alone is 
not sufficient to explain the efficacy. Flow cytometric and microscopy analyses of the tumors 
ex vivo showed that unresponsiveness was not linked to target downregulation (Fig.4c,d, Fig. 
S10). Mice treated with CD318 CARs showed increased infiltration of T cells, CAR T cells and 
macrophages as compared to those treated with CD66c CAR T cells, whereas the composition 
of central memory (TCM) and effector memory (TEM) phenotypes did not differ significantly 





Fig. 3: Evaluation of CAR T cell in vivo functionality in an AsPC1 xenograft model. (a) Representative 
bioluminescence images of tumor bearing NSG mice. Tumors were induced by subcutaneously transplanting 
Luciferase expressing AsPC1 cells (Color scale for all images, min = 1x109, max = 1x1011). Mice were randomized 
and treated upon established solid tumors reached 25 mm² (day 7) by intravenous infusion of 5x106 CAR T cells 
or Mock T cells. (b) Development of tumor burden for individual mice treated either with Mock T cells or with 
the respective CAR T cells (Mock: n = 6, CD66c S: n = 5, CD318 XS: n = 7, TSPAN8 S: n = 4, TSPAN8 L: n = 
6). (c) Average bioluminescence signal ± s.e.m. of the respective treatment groups (n equal to b). (d) Average 




Fig. 4: Ex vivo analysis of the T cell phenotype and AsPC1 derived tumor tissues upon treatment with CAR 
T cells. (a) Number of CAR T cells in the spleen at the end of the experiment 27 d post CAR T cell injection 
(CD66c S: n = 4, CD318 XS: n = 6, TSPAN8 S: n = 4, TSPAN8 L: n = 5). (b) Phenotype of CAR T cells in the 
spleen at the end of the experiment 27 d post CAR T cell injection, as demonstrated by the percentage of TCM and 
TEM (n equal to a). All data are shown as mean ± s.e.m. (c) Representative immunofluorescence images of (CAR) 
T cell tumor infiltration, macrophage tumor infiltration and target expression (CD318 XS tumor 9 days post CAR 
T cell injection, CD66c S tumor 27 days post CAR T cell injection). (d) Density plots of a dissociated AsPC1 
xenograft showing CD66c expression 35 days post injection of 5e6 CD66c S Vl-Vh CAR T cells (top) and the 







To confirm the robustness of our results, we challenged these CAR constructs in a second 
preclinical setting using BxPC3 and an increased dose 1x107 CAR T cells (Fig. 5a-c). As seen 
previously, Mock T cells lacked therapeutic effect (Fig. S9). The CD318 XS CAR again 
achieved a complete tumor eradication showing a fast kinetic. TSPAN8 S CARs showed a 
higher therapeutic functionality as the L spacer but both only induced stable tumor burden. In 
this model, no therapeutic effect was observed for the CD66c S CARs, correlating with the poor 
outcome in the first study. Reduced efficacy of the TSPAN8 CARs could be caused by reduced 
target expression of this tumor model as compared to the AsPC1 xenograft (Fig. S10). As 
observed for AsPC1 , reduction of the tumor size was delayed as a result of T cell and 
macrophage infiltration (Fig. 6c). Analysis of the total T cell counts in the spleen at the end of 
the study confirmed that higher CAR T cell counts correlated with higher efficacy, again CD66c 
CAR T cells being the exception (Fig. 6a). T cell phenotyping revealed a decrease in the TCM 
compartment (Fig. 6b) within the CD66c S CAR T cells as compared to all other CAR treated 
groups.  
In conclusion, we could verify therapeutic efficacy of our CAR constructs at different 
therapeutic magnitudes ranging from tumor control to total tumor eradication and revealed an 
overall high correlation among both in vivo studies. In addition, low-responsiveness – as seen 
for the CD66c construct – was not linked to target downregulation but rather to decreased CAR 




Fig. 5: Evaluation of CAR T cell in vivo functionality in a BxPC3 xenograft model. (a) Representative 
bioluminescence images of tumor bearing NSG mice. Tumors were induced by subcutaneously transplanting 
Luciferase expressing BxPC3 (Color scale for all images, min = 1x108, max = 1x1010). Mice were randomized and 
treated upon established solid tumors reached 25 mm² (day 15) by intravenous infusion of 1x107 CAR T cells or 
Mock T cells. (b) Development of tumor burden for individual mice treated either with Mock T cells or with the 
respective CAR T cells (Mock: n = 6, CD66c S: n = 6, CD318 XS: n = 6, TSPAN8 S: n = 6, TSPAN8 L: n = 6). 
c, Average bioluminescence ± s.e.m. of the respective treatment groups (n equal to b). (d), Average tumor size ± 




Fig. 6: Ex vivo analysis of the T cell phenotype and AsPC1 derived tumor tissues upon treatment with CAR 
T cells. (a) Number of CAR T cells in the spleen at the end of the experiment 25 d (CD66c S) and 27 d post CAR 
T cell injection (CD66c S: n = 2, CD318 XS: n = 2, TSPAN8 S: n = 4, TSPAN8 L: n = 4). (b) Phenotype of CAR 
T cells in the spleen at the end of the experiment 25 d (CD66c S) and 27 d post CAR T cell injection, as 
demonstrated by the percentage of TCM and TEM (n equal to a). All data are shown as mean ± s.e.m. (c) 
Representative immunofluorescence images of (CAR) T cell tumor infiltration, macrophage tumor infiltration and 
target expression (CD318 XS tumor 10 days post CAR T cell injection, CD66c S tumor 25 days post CAR T cell 
injection). 
CD318 is the most promising candidate with respect to functionality and safety  
The bioinformatical analysis of CD66c, CD318 and TSPAN8 showed that all of them have 
restricted but detectable expression on healthy tissues (Tab. S1, Fig. S3), implying the need for 
an evaluation of safety concerns prior to a possible clinical translation. To overcome the 
inconsistency of publicly available databases we analyzed protein expression and localization 
by cyclic IF on 17 healthy tissues.  
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Quantification of protein expression supported our initial findings that all three target 
candidates showed a much stronger expression on PDAC tissue as compared to all healthy 
tissues analyzed. CD318 showed the most favorable pattern with almost no detectable protein 
expression in healthy tissues. The only relevant but very low expression was restricted to the 
luminal side of the colon whereas T cells would most likely sense the basal or lateral membranes 
(Fig. S11). TSPAN8 showed a strong expression in the gastrointestinal tract, especially on colon 
(Fig. 7a, Fig. S12) which harbors the risk of toxicity induced by CAR T cells, whereas the weak 
staining observed in the medulla and skeletal muscle (Fig. S12) seemed to derive from 
unspecific binding as the subtraction of the background signal resulted in a negative value (Fig. 
7a). In case of CD66c, some expression was observed in the hair follicle (Fig. S13) which might 
display a tolerable risk similar to expression detected in the ovary but limited to non-cellular 
mucus regions. A weak expression was present in lung tissue but much lower as compared to 
PDAC tissue (Fig. 7a) which might allow for a therapeutic window. 
In addition, we measured expression of the three candidates on blood cells from healthy donors 
by flow cytometry as hematopoietic tissue displays a particular risk factor due to the presence 
of numerous putative target expressing cells in the preferred niche of CAR T cells. Flow 
cytometry based analyses showed expression of CD66c but not CD318 or TSPAN8 on several 
hematopoietic lineages (Fig. 7b). Whereas only minor subpopulations where CD66c-positive, 
the myeloid lineage, neutrophils in particular, showed a strong expression. In conclusion, 
CD318 is the most promising candidate for a future clinical translation in terms of predicted 
safety and efficacy, while in the case of TSPAN8 and CD66c safety concerns arose with respect 





Fig. 7: Off-tumor target expression and co-culture of CAR T cells and healthy cells. (a) Quantification of 
target expression within different healthy tissues. Depicted is the background corrected mean fluorescence 
intensity of the respective tissues. Data represent mean ± SD. (b) Flow cytometric analysis of target expression on 
lysed blood samples. Data represent mean ± SD of three donors. 
Discussion  
In the present study, we performed an empirical screening with the aim to identify novel CAR 
target candidates for the treatment of PDAC, identifying four novel target candidates: CLA, 
TSPAN8, CD66c and CD318. We were the first discovering CLA to be expressed on epithelial 
derived tumors. Until now, CLA was only known to be a unique skin-homing receptor, 
expressed on subsets of T cells, B cells, NK cells, Langerhans cells, monocytes and dendritic 
cells (14,16-19). It is a specialized glycosylated form of SELPLG and plays a role in tissue 
infiltration of immune cells through binding to E-, L- and P-selectins (25). Since it is only 
expressed on subsets of these cell types, we hypothesized that it might be a suitable CAR T cell 
target with acceptable off-tumor toxicities. However, as its expression was upregulated on 
activated T cells it posed a technical roadblock producing functional CAR T cells. CLA specific 
CAR T cells performed much worse underlining the intrinsic problem of CAR T cells specific 
for self-antigens. Other research groups developed potential solutions to this problem. While 
some suggested a CRISPR/Cas mediated knock-out of the antigen within the T cells (26,27) 
others advocate to trap self-antigens in the T cells, using an ER retention domain coupled with 
an scFv specific for the self-antigen (28).  
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The other identified target candidates CD66c, CD318 and TSPAN8 have been described to be 
overexpressed in several cancer entities (29-36). With the combination of our antibody driven 
screenings and the comprehensive bioinformatical and immunofluorescence analysis we could 
add the crucial knowledge that the expression of these target candidates is not only highly 
enriched in PDAC tumor cells but off-tumor expression within the human body is restricted as 
well. A strong support for the validity of this approach is that we identified targets which are 
under investigation for CAR T cell based treatment already, such as CEACAM5 (CEA) or 
PROM1 (CD133)(8).  
We evaluated 32 CAR constructs differing in scFv orientation and spacer length in vitro. While 
in the case of CD318 and CD66c the shorter spacer versions showed highest functionality, 
TSPAN8 specific constructs based on longer spacers performed better. CD318 has the longest 
extracellular amino acid chain (638), followed by CD66c (320) and TSPAN8 (24 and 96). 
Despite lacking knowledge on the exact epitope of the scFvs and the 3D structure of the 
extracellular domains, these findings nicely align with previous investigations pointing out that 
longer spacers are superior for membrane proximal epitopes and vice versa (37,38).  
Finally, we could show that our four best performing constructs in vitro also exhibited anti-
tumor efficacy in two independent preclinical studies. The CD318 XS Vh-Vl and the TSPAN8 
S Vh-Vl CARs turned out to be very promising candidates for further pre-clinical and possibly 
clinical evaluation based on their high efficacy. The CD66c S Vl-Vh CAR was lagging behind 
its in vitro efficacy but could still induce disease stabilization in one of the two xenograft 
models. We could show that the decreased activity of the CD66c specific CAR T cells was not 
caused by target downregulation and that the CAR T cell count in the spleen was indifferent to 
other treatment groups, therefore excluding persistence as an issue. At the tumor site, we found 
decreased macrophage and CAR T cell infiltration, suggesting that infiltration and possibly 
activation of the CAR T cells may be impaired. Other studies have shown that tonic signaling 
can cause such differences among in vitro and in vivo studies (39). However, we did not observe 
background activation of CAR T cells co-cultured with target-negative cells. Further studies 
are needed to elaborate on how to functionally improve this CAR or evaluate further constructs 
specific for CD66c which might show better functionality in vivo. 
With respect to a possible clinical translation, we could corroborate the overlapping expression 
of CD66c and CEA, making it an interesting target candidate. In fact, it has been shown that 
CD66c is even stronger over-expressed in malignant tissues than CEA (40). This finding might 
help to manufacture fine-tuned CARs that can differentiate among differential expression levels 
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on tumor and healthy cells, as shown by Caruso et al. for the target EGFR (41). However, the 
expression level of CD66c on neutrophils and other myeloid lineages, underlines a strong risk 
for inducing a severe cytokine-release-syndrome (CRS) by massive CAR T cell reactivity in 
the blood as observed in B-ALL patients treated with CD19 specific CAR T cells, in particular 
observed in patients with high tumor burden (6). However, while CRS and B cell aplasia can 
be treated quite well, neutropenia can only be tolerated in a very short time window rendering 
CD66c a high risk target, at least in a single-specificity CAR T cell approach (42). 
Combinatorial approaches using Boolean logic gating such as AND or NOT CAR constructs 
might offer an alternative to circumvent the expected toxicities (43-45). In this respect, also 
combinations of established targets such as MSN or CD133 and the novel targets described 
herein will broaden the repertoire to specifically target pancreatic tumor cells. Further 
alternatives would be the development of CARs tuned to distinguish among levels of antigen 
expression on tumor vs. healthy cells (41) or a tight control of time and dose of binder 
administration, such as anti-FITC–directed CAR-Ts or UNI-CARs (46,47). In addition, spatial 
control of CAR expression or activation may add a further level of safety (48). These 
approaches have the potential to overcome on-target off-tumor toxicities as seen with single 
target specific CAR T cells.  
CD318 and TSPAN8 have been suggested as targets for pharmacological or antibody driven 
therapies (49-51). While these studies show decreased tumor growth rates or disease 
stabilization in vitro and in vivo, our results showed complete tumor eradication, which is most 
likely owed to the superior cytotoxicity of T cells representing a “living drug”. This has been 
shown in B-cell malignancies by achievement of complete disease remission upon CD19 
specific CAR T cell administration after failure of prior CD19 specific antibody therapy. 
However, as CAR T cells are more efficient than antibodies and their pharmacokinetics hard to 
predict and control, they have to be administered cautiously for potential off-tumor toxicities. 
Our analyses aiming at predicting tissues at risk suggested that CD318 has the most favorable 
pattern with almost no detectable protein expression in healthy tissues. Based on our results, 
the highest risk for TSPAN8 specific toxicities were predicted in the gastro intestinal tract, in 
particular for colon, probably similar to those observed for CEA directed CARs (52). Similar 
to CEA, using an alternative CAR T cell infusion route into the hepatic artery might be a 
solution to overcome this possible health threat (53). In addition, the toxicity towards colon 
tissue could potentially be further reduced using an AND CAR strategy, with CAR T cells only 
being activated, when they face both CD318 and TSPAN8.  
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In summary, this study is the first example combining an empiric antibody based flow 
cytometry screen with a novel cyclic immunofluorescence imaging platform and a 
comprehensive bioinformatical and experimental evaluation for off-tumor expression to 
identify PDAC specific cell surface markers. We identified four novel target candidates, CLA, 
CD66c, CD318 and TSPAN8, for a possible cellular immunotherapy of PDAC by CAR T cells. 
CARs specific for CD66c, CD318 and TSPAN8 showed functionality in vitro and in vivo, with 
CD318 being the most favorable candidate for a clinical translation. 
Materials and Methods  
Antibody screening on patient derived xenografts  
All pancreatic ductal adenocarcinoma (PDAC) patient derived xenografts (PDX) were obtained 
from Charles River Discovery Research Services Germany GmbH. PDX models were 
dissociated using the Tumor Dissociation Kit, human in combination with the gentleMACS™ 
Octo Dissociator with Heaters (both Miltenyi Biotec). Subsequently, mouse cells were depleted 
using the Mouse Cell Depletion Kit (Miltenyi Biotec). Resulting cell suspensions were analyzed 
using the MACS® Marker Screen, human (Miltenyi Biotec) a monoclonal antibody panel 
containing 371 pre-titrated antibodies with 9 isotype controls, or candidate antibodies selected 
from this panel for subsequent screening steps (Fig. S1). All samples were measured on a flow 
cytometer.  
Bioinformatical data mining and ranking  
After assigning gene symbols to the 50 top PDX-based target candidates, the corresponding 
gene and protein expression data were retrieved from the following data sources: Human 
Protein Atlas (20) (v15, https://www.proteinatlas.org/), ProteomicsDB (21) 
(https://www.proteomicsdb.org/), human proteome map (22) 
(http://www.humanproteomemap.org/), Genotype-Tissue Expression (GTEx, 
https://gtexportal.org/) and genevestigator (54).  
Human Protein Atlas (HPA) – antibody-based  
Protein expression scores in HPA are based on immunohistochemical data manually scored 
with regard to staining intensity and fraction of stained cells. We determined the fraction of the 
86 cell and tissue types listed in HPA assigned to the protein expression levels “not detected”, 
“low/medium”, and “high”. The top 50 target candidates were sorted based on the fraction of 
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“not detected” cell types in descending order. Within a group of candidates exhibiting the same 
fraction of not detectable cell types, candidates were further sorted based on the fraction of 
“medium/high” cell types in ascending order.  
Human Protein Atlas (HPA) – RNAseq  
At the time of data download, gene expression scores in HPA were based on FPKM values. We 
determined the fraction of the 32 tissue types listed in HPA assigned to the gene expression 
levels “not detected” (<1fpkm), “low/medium” (1-50fpkm), and “high” (>50fpkm). The top 50 
target candidates were sorted based on the fraction of “not detected” cell types in descending 
order. Within a group of candidates exhibiting the same fraction of not detectable cell types, 
candidates were further sorted based on the fraction of “medium/high” cell types in ascending 
order.  
ProteomicsDB (PDB) – Mass spectrometry-based  
Protein expression data were retrieved as log10 normalized iBAQ intensity values. We 
determined the fraction of the 66 tissue types listed in ProteomicsDB with missing protein 
expression values for the top 50 target candidates and ranked them in descending order. Only 
peptides unique to the target protein were considered.  
Human Proteome Map (HPM) – Mass spectrometry-based  
Protein expression data were retrieved as intensity levels scaled from 1 (lowest) to 10 (highest). 
We determined the fraction of the 17 adult tissue types and 6 cell types listed in HPM assigned 
to the arbitrarily defined protein expression levels “not detected/low” (levels 0-3), “medium” 
(4-7), and “high” (8-10). The top 50 target candidates were sorted based on the fraction of “not 
detected” tissues in descending order. Within a group of candidates exhibiting the same fraction 
of not detectable cell types, candidates were further sorted based on the fraction of 
“medium/high” cell types in ascending order. Only peptides unique to the target protein were 
considered.  
GTEx – RNAseq  
The data used for the analyses described in this manuscript were obtained from 
GTEx_Analysis_2016-01-15_v7_RNASeQCv1.1.8. We determined the fraction of the 30 
tissue types listed in GTEx assigned to the median gene expression levels “not detected” 
(<1tpm), “low/medium” (1-50tpm), and “high” (>50tpm). The top 50 target candidates were 
sorted based on the fraction of “not detected” tissues in descending order. Within a group of 
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candidates exhibiting the same fraction of not detectable cell types, candidates were further 
sorted based on the fraction of “medium/high” cell types in ascending order.  
Genevestigator  
Gene expression data (log2 space) were extracted from the Genevestigator collection of 
microarray data (species: Homo sapiens, platform: Affymetrix Human Genome U133 Plus 2.0, 
sample status: healthy; root: cell type. Hierarchical categories with identical expression values 
were condensed). Two-dimensional hierarchical clustering was performed using MeV 4.9.0 
(http://mev.tm4.org, distance metric: Euclidean distance, linkage method: complete linkage 
clustering; leaf order optimization: genes and samples).  
Rank sum  
The final rank was calculated based on the quotient of the rank sum from all data sources 
divided by the number of data sources it was found in. 
Ranking according to Perna et al. (2017)  
Perna and colleagues (23) developed an algorithm to identify expression of target candidates 
throughout the human body using HPA, PDB and HPM as input databases. We recreated their 
method using publicly available data sets and a few methodological differences. We also log10 
transformed the data from HPM and PDB but did not perform a temporarily correction of HPM 
data for multiple gene assignments. Subsequently, normal distributions were fitted to the data 
using the Levenberg-Marquardt method. For some data sets this required ignoring data close to 
zero which we assume is noise introduced by various effects (for instance genes never expressed 
in certain tissue types) and which did not fit in with a normal distribution. This curve fitting 
produced the average and standard distribution values we used and peak maximum and standard 
deviation were calculated for each curve.  
Data were then binned as follows: Expression values between the maximum peak and one 
standard deviation above were considered “medium” (2). Values above this threshold were 
considered to be “high” (3) expressed. Expression values between the peak maximum and the 
standard deviation below were considered “low” (1) and all values below this threshold were 
categorized as “not detected” (0).  
As the tissue names differed between the different data bases, they were harmonized to a 
consensus tissue name as suggested by Perna et al. (Tab S1). The final table was then created 
in depicting the highest value for the respective tissue and target candidate from all data bases.  
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Cyclic immunofluorescence staining  
Primary or PDX derived PDAC specimens and healthy tissues were embedded in Tissue 
Freezing Medium (Leica) and stored at -70°C until further use. Afterwards, three 8 μm sections 
were cut on a CM3050 S cryostat (Leica), collected on SuperFrost® Plus slides (Menzel) and 
stored no longer than 2 weeks at -70°C. On the day of use, sections were thawed in -20°C 
acetone and then processed for hematoxylin and eosin (HE) or immunofluorescence (IF) 
staining.  
For HE staining the acetone fixed section was dipped thrice in water and then incubated in 
Meyer’s hematoxylin solution (Carl Roth) for 7 min. The section was transferred for 5 min into 
water and subsequently shortly dipped into HCl/ethanol solution (1% HCl, 70% ethanol). 
Afterwards, it was rinsed with water and stained in Eosin/ethanol solution (0.5 g Eosin Y in 
100 ml 70% ethanol) for 5 min. The section was then dehydrated stepwise first in 70% ethanol, 
then 96% ethanol and finally pure ethanol with 3 dips for each concentration. Following this, 
the tissue was cleared in two changes xylene (Carl Roth) with three dips each. The HE stained 
section was covered in Roti®-Histo Kit (Carl Roth) and cover slipped. Subsequently the section 
was examined using a light microscope to define a region of interest, which was confirmed by 
a pathologist to be a neoplastic region.  
After definition of a region of interest, another 8 μm section of the same specimen was thawed 
in -20°C acetone. The fixed tissue was stored shortly in autoMACS™ Running Buffer (Miltenyi 
Biotec) and introduced into a MACSima™ prototype. MACSima™ is a novel cyclic IF imaging 
platform enabling fully automated IF imaging of individual biological samples. The system 
operates by iterative fluorescent staining, image acquisition, and signal erasure, using multiple 
fluorochrome-labeled antibodies per cycle (manuscript under preparation). Images that were 
generated using MACSima™ were overlaid and analyzed using ImageJ 1.49v.  
Healthy tissue microarray analysis and quantification of expression  
HDR images were checked manually using ImageJ 1.49v for any structures that could disturb 
the subsequent automated analysis. Therefore, images containing clumped conjugates, swollen 
nuclei, fabric remnants or other artefacts were excluded from further analysis. All other images 
were uploaded into the CellProfiler v2.2.0 software (55). We defined cell nuclei by DAPI 
staining as primary objects and excluded nuclei touching the image border. Secondary objects 
were defined as primary objects expanded by 5-6 pixels depending on the nuclei density, 
allowing us to approximate the shape of a cell. We then extracted the mean fluorescence 
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intensities of the respective target candidate for each cell (secondary object). In order to define 
a background, we used the unspecific REA control (S) antibody as an isotype control and 
subtracted the control intensity from the target candidate intensity. For image display in the 
figures, we uploaded the respective PDAC image of each target to ImageJ and auto adjusted it. 
We then uploaded all other tissue images of the same excitation time and adjusted the display 
to the same parameters as for the PDAC image.  
Flow cytometric analysis of primary PDAC specimen  
The tumors were dissociated using the Tumor Dissociation Kit, human in combination with the 
gentleMACS™ Octo Dissociator with Heaters (both Miltenyi Biotec) and prepared for flow 
cytometry as described above.  
Cell lines and culture conditions  
Human embryonic kidney 293T (HEK293T), BxPC3 and AsPC1 cells were obtained from 
ATCC and cultured as recommended. For co-culture with T cells they were transduced to 
express firefly luciferase (Luc) and green fluorescent protein (GFP). The PanCa0201 cell line 
was derived from a human primary PDAC biopsy, dissociated as described above and tumor 
cells isolated prior to seeding using the Tumor Cell Isolation Kit, human (Miltenyi Biotec). 
Subsequently tumor cells were cultivated using the Pancreas TumorMACS Medium (Miltenyi 
Biotec). The PanCa0201 cell line was transduced as well to express Luc and GFP. To validate 
authenticity of the cell lines used, we used the Human STR Profiling Cell Authentication 
Service (ATCC).  
Isolation of T cells and generation of CAR T cells  
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation 
from buffy coats of healthy anonymous donors (German Red Cross Dortmund). T cells were 
purified from PBMCs using the Pan T Cell Isolation Kit, human (Miltenyi Biotec) and activated 
in TexMACS™ Medium (Miltenyi Biotec) containing T Cell TransAct™, human (Miltenyi 
Biotec) and 100 IU/ml of recombinant Human IL-2 IS, research grade (IL-2) (Miltenyi Biotec) 
or 12.5 ng/mL of recombinant human interleukin IL-7 and 12.5 ng/mL of recombinant human 
IL-15 (both Miltenyi Biotec) for the CLA expression experiments. T cells were transduced 24 
h after activation using vesicular stomatitis virus glycoprotein G (VSV-G) pseudotyped 
lentiviral supernatants derived from transfected HEK293T cells. Supernatants were 
concentrated and stored at -70°C until transduction. 3 d post activation, T Cell TransAct™, 
human was washed out of the medium and T cells were cultured with 100 IU/ml IL-2 containing 
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TexMACS™ Medium. T cells were used for in vitro assays directly or frozen until further use 
for in vivo testing 12-14 d after purification from PBMCs. Frozen T cells that were used for in 
vivo testing were thawed 24 h before injection in TexMACS™ Medium without further 
supplements. On the day of use, the amount of living CAR T cells was determined using flow 
cytometry and staining T cells with 7-AAD and anti-human LNGFR (both Miltenyi Biotec).  
Generation of CAR plasmids  
Plasmids encoding the CAR constructs were prepared using standard molecular biology and 
cloning techniques. They all comprised murine single-chain variable fragments (scFvs) specific 
for the respective target candidates (CLA, CD66c, CD318 or TSPAN8) that were preceded by 
a CD8α leader peptide. Sequences for the light and heavy chain of the scFvs were the same, as 
for the antibodies used during target discovery. scFvs were used in both possible orientations 
and connected with a glycine-serine linker. scFvs were followed by spacers differing in size. 
The library of backbones comprised either a human IgG4 hinge from the CH2-CH3 domains 
(L; long spacer; 228 aa), a human IgG4 hinge from the CH3 domain (medium spacer; 119 aa), 
a human IgG4 hinge from the sequence between CH2 and CH1 domain (XS; extra short spacer; 
12 aa) or a human CD8α spacer (S; short spacer; 45 aa). All IgG4 spacer domains contained a 
4/2 NQ mutation in the CH2 domain as well as a S→P substitution in the hinge region in order 
to reduce FcR binding All CARs shared the same CD8α transmembrane domain and featured 
4-1BB/CD3ζ derived intracellular signaling domains. The CAR sequence was linked to a P2A 
sequence to induce co-expression of truncated low-affinity nerve growth factor receptor 
(LNGFR).  
Target-T cell co-culture assays  
Target cells were inoculated in duplicates in 96-well culture plates at densities of 1x104 - 5x104 
cells per well in 100 μl of their respective culture medium. Directly thereafter or 24 h later 
CAR+ T cells were added in E:T ratios of either 5:1, 2:1, or 1:1. Final vessel volume equaled 
200 μl. The amount of T cells in the Mock control was adjusted to the number of total T cells 
in the CAR group with the highest total cell count. Cytotoxicity was measured as a decrease in 
green surface area with an IncuCyte® S3 Live-Cell Analysis System (Sartorius). The surface 
area at the start of the experiment was considered 100% and the following decrease or increase 
in surface area was set into relation. At the end of co-culture, either after 48 h or 6 d, CAR T 
cells were analyzed with a flow cytometer for their expression of TIM-3 or 4-1BB, LAG-3, and 
PD-1. In addition, after 48h 100 μl of medium were used for analysis of the cytokine release. 
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In case co-culture continued, 100 μl of fresh target cell medium were added again. Cytokine 
content was measured with the MACSPlex Cytokine 12 Kit, human (Miltenyi Biotec).  
Normalization for in vitro killing, cytokine release and marker expression for cross-
comparability  
To better compare the effectivity of the CAR constructs between cell lines, assays and donors, 
we normalized the readouts for each assay. We normalized the cytokine release of GM-CSF , 
IL-2, TNF-α and INF-γ to the highest value for each cytokine and calculated from them an 
average resulting in the cytokines value. We normalized to the highest number of CAR+ cells 
expressing the respective marker, with the markers being PD-1, LAG-3, TIM-3, 4-1BB and 4-
1BB/LAG-3 double positive. We calculated then the average of the normalized values resulting 
in the marker value. For killing we used the highest decrease after 48 h and 6 d in green surface 
area as value to normalize to. Again the average of 48 h and 6 d values resulted in the killing 
value. Balloon diagrams were created using R (v3.4) with the packages reshape2, ggplot2 and 
viridis.  
Preclinical mouse models  
All experiments were approved by the Governmental Review Committee on Animal Care in 
NRW, Germany and performed according to guidelines and regulations (Landesamt für Natur, 
Umwelt and Verbraucherschutz NRW, Approval number 84-02.04.2017.A320). Cell line 
derived xenografts were established by injecting 1x106 BxPC3 or AsPC1 cells subcutaneously 
in the right flank of NOD SCID gamma (NSG; NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice 
(Jackson Laboratory, Bar Harbor, USA , provided by Charles River). Once tumors reached 25 
mm² as measured with a caliper, 5x106 or 1x107 CAR T cells were injected into the tail vein. 
The amount of injected Mock T cells was adjusted to the number of total T cells in the CAR 
group with the highest total cell count. Anti-tumor response was measured longitudinally using 
an in vivo imaging system (PerkinElmer, Waltham, USA) after intraperitoneal injection of 100 
μL (30 mg/mL) D-Luciferin (Potassium Salt, LUCK-2G, GoldBio). All measures to secure the 
wellbeing of mice were executed following the relevant animal use guidelines and ethical 
regulations. Where possible, tumors were excised and cut in two halves. One half was 
embedded in Tissue Freezing Solution (Leica) and stored at -70°C until further use. The other 
half was dissociated as stated above and T cells were analyzed using flow cytometry. Ex vivo 
analysis of the spleen was performed after dissociation using the gentleMACS™ Octo 
Dissociator with Heaters according to the manufacturers protocol (Miltenyi Biotec) and red 
blood cell lysis using Red Blood Cell Lysis Solution (Miltenyi Biotec) using a flow cytometer.  
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Flow cytometry  
All samples were measured on a MACSQuant® Analyzer 10 and analyzed using the 
MACSQuantify™ Software. Antibody conjugates that were used for surface marker expression 
on PDAC primary tissues, PDXs and T cell analysis were the same as in the MACS Marker 
Screen. Only conjugated fluorophores were exchanged for some instances. From Thermo 
Fisher: Chicken anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647. 
From Merck: Anti-Mouse IgG (Fab specific) antibody produced in goat.  
Stainings conducted with antibody conjugates from Miltenyi Biotec. were performed as 
recommended by the supplier. Therefore, conjugates were added to cell suspensions in a final 
ratio of 1:11 and incubated 10 min at 4°C. Antibodies from Sigma-Aldrich and Thermo Fisher 
were applied at concentrations of 10 μg/ml and incubated for 30 min at 4°C. Subsequent to the 
incubation a washing step was performed adding PEB in an excess of 9 times the staining 
solution. Cells were spun down and resuspended in appropriate volumes of PEB and measured 
on a flow cytometer. Dead cells were excluded using PI or 7-AAD. 
Statistics  
Unless otherwise specified, all graphs show the mean with error bars representing the standard 
error of the mean. Statistical comparisons between more than two groups were conducted by 
Two-way ANOVA with p-value <0.05 using GraphPad Prism 7. For all mouse experiments, 
the number of independent mice used is listed in the figure legend. For cytokine, marker and in 
vitro cell killing experiments, n = 2 wells, and experiments were repeated at least twice.  
Ethical concerns  
For all studies using human PDAC primary tissue, written informed consent was obtained 
following the guidelines of the approved Universitätsmedizin Göttingen Review Board 
protocol.  
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy 
anonymous volunteers that were purchased from the German Red Cross Dortmund. All blood 
samples were handled following the required ethical and safety procedures.  
All animal experiments were approved by the Governmental Review Committee on Animal 
Care in NRW, Germany and performed according to guidelines and regulations.  
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 Fig. S1: Target discovery workflow. Scheme of the workflow for identification of novel target candidates as 




Fig. S2: Gating strategy for flow cytometric target candidate analysis of dissociated patient derived 
xenograft tissues. Representative flow cytometric analysis of two patient derived xenograft models. Tumor tissue 
was dissociated into a single cell suspension, stained with the respective antibodies and analyzed by flow 
cytometry. Debris was excluded by SSC-A/FSC-A gating (a) and dead cells were excluded using PI or 7-AAD 
(b). After exclusion of doublets (c) mouse cells were excluded by gating on hEpCAM+ human tumor cells (d). One 
xenograft was stained before with CellTrace™ Violet to distinguish between both samples (d). The target 




 Fig. S3: Bioinformatics based ranking of target candidates. (a) 20 most promising candidate genes ranked by 
the quotient of the rank sum and number of data sources the respective gene was found in. The ranking also 
includes targets currently under clinical investigation which 50 appeared in our ranking but were not included in 
the initial antibody array or failed to meet inclusion criteria during the PDX screening (blue filling). Final rank 
with lowest off-tumor expression at the top; HPA RNAseq or antibody = Human Protein Atlas mRNA or antibody-
based protein expression, HPM = Human Proteome Map, GTEx = Genotype-Tissue Expression. (b) Heatmap of 




Fig. S4: Gating strategy for flow cytometric target candidate analysis of dissociated primary pancreatic 
ductal adenocarcinoma. Representative flow cytometric analysis of a primary pancreatic ductal adenocarcinoma. 
Tumor tissue was dissociated into a single cell suspension, stained with the respective antibodies and analyzed by 
flow cytometry. Debris (a), dead cells (b) and doublets were excluded (c). Target candidate expression was 
analyzed on leukocytes (CD45+), tumor cells (EpCAM+) or double negative cells (d, e, f, g). (h) Representative 




Fig. S5: Expression of LNGFR and CAR in HEK293T cells lipofected with the CAR constructs. Frequency 
of HEK293T cells which are expressing LNGFR and the respective CAR on the cell surface as measured by flow 
cytometry. HEK293T cells were lipofected with CAR plasmids to assess the general ability of the CAR cassette 
in the plasmid to be expressed (as measured by the reporter protein LNGFR) and if the CAR construct can be 




Fig. S6: CAR T cells specific for CLA, CD66c, CD318 and TSPAN8 exhibit no cytotoxic effects on target 
negative cells. (a) 1x105 CAR T cells were inoculated with 5x104 HEK293T cells in a 96-well cavity. The amount 
of Mock T cells was adjusted to the CAR group with the highest amount of total T cells per well. Killing was 
measured as percentage difference of green surface area measured automatically with an IncuCyte S3 device. 
Values represent mean ± s.e.m (n = 2). (b) Activation marker expression upon culture without any stimulus or 
with PMA/Ionomycin stimulation. Shown are the means ± s.d. (n=2). Activation marker expression was measured 




Fig. S7: Evaluation of CAR T cell functionality in vitro. (a) Results of the initial screening assays. Average 
relative target cell killing, cytokine release, marker upregulation and overall performance (displayed as circle size, 
x axis) for the respective CAR constructs (y axis). The number of replicates is indicated in parentheses behind the 
construct name. (First value = n of killing assays, second value = n of cytokine release assays, third value = n of 
marker upregulation measurements). (b) Representative result for the kinetics of AsPC1 target cell killing by the 
best performing CAR constructs. (c) Representative results showing cytokine release and activation marker 
expression patterns upon co-culture with AsPC1 target cells. Shown are the means ± s.e.m (n=2). Activation 
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Figure S8: CLA is a expressed on T cells and upregulated upon activation. (a) Expression of CLA and its 
protein backbone CD162 on T cells upon activation and expansion for 7 days. (b) Kinetic of CLA and CD162 
expression on T cells followed over 7 days. Depicted are the single measurements of three donors. Isolated T cells 
were activated with T Cell TransAct™, human and cultivated in medium either supplemented with 100 IU/ml IL-
2 or 12.5 ng/mL of recombinant human interleukin IL-7 and 12.5 ng/mL of recombinant human IL-15. (c) 
Although the CAR cassette is functional based on LNGFR expression, the a anti-CLA CAR is expressed only at 




Fig. S9: Mock T cells have no effect on tumor outgrowth in both in vivo models. (a) Tumor burden of mice 
treated either with Mock T cells or untreated. Left: Mice injected with 1x106 AsPC1 cells (Mock: n = 6, Untreated: 
n = 5). Right: Mice injected with 1x106 BxPC3 cells (Mock: n = 6, Untreated n = 4). (b) Kaplan-Meier plots of 




Fig. S10: Analysis of target expression upon xenotransplantation of AsPC1 and BxPC3 cells in vivo. The 
expression of the target candidates was evaluated upon xenotransplantation of AsPC1 and BxPC3 cells in vivo. 
Tumors were grown for 30 days, resected and analyzed for target expression by (a, b) flow cytometry, and (c) 




Fig. S11: CD318 expression on healthy tissues assessed by cyclic immunofluorescence imaging. 




Fig. S12: TSPAN8 expression on healthy tissues assessed by cyclic immunofluorescence imaging. 





Fig. S13: CD66c expression on healthy tissues assessed by cyclic immunofluorescence imaging. 
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Abstract 
A domain that is often neglected in the assessment of chimeric antigen receptor (CAR) 
functionality is the extracellular spacer module. However, several studies have elucidated that 
membrane proximal epitopes are best targeted through CARs comprising long spacers, while 
short spacer CARs exhibit highest activity on distal epitopes. This finding can be explained by 
the requirement to have an optimal distance between the effector T cell and target cell. 
Commonly used long spacer domains are the CH2-CH3 domains of IgG molecules. However, 
CARs containing these spacers generally show inferior in vivo efficacy in mouse models 
compared to their observed in vitro activity, which is linked to unspecific Fcγ-Receptor binding 
and can be abolished by mutating the respective regions. Here, we first assessed a CAR therapy 
targeting membrane proximal CD20 using such a modified long IgG1 spacer. However, despite 
these mutations, this construct failed to unfold its observed in vitro cytotoxic potential in an in 
vivo model, while a shorter but less structured CD8α spacer CAR showed complete tumor 
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clearance. Given the shortage of well-described long spacer domains with a favorable 
functionality profile, we designed a novel class of CAR spacers with similar attributes to IgG 
spacers but without unspecific off-target binding, derived from the Sialic acid-binding 
immunoglobulin-type lectins (Siglecs). Of five constructs tested, a Siglec-4 derived spacer 
showed highest cytotoxic potential and similar performance to a CD8α spacer in a CD20 
specific CAR setting. In a pancreatic ductal adenocarcinoma model, a Siglec-4 spacer CAR 
targeting a membrane proximal (TSPAN8) epitope was efficiently engaged in vitro, while a 
membrane distal (CD66c) epitope did not activate the T cell. Transfer of the TSPAN8 specific 
Siglec-4 spacer CAR to an in vivo setting maintained the excellent tumor killing characteristics 
being indistinguishable from a TSPAN8 CD8α spacer CAR while outperforming an IgG4 long 
spacer CAR and, at the same time, showing an advantageous central memory CAR T cell 
phenotype with lower release of inflammatory cytokines. In summary, we developed a novel 
spacer that combines cytotoxic potential with an advantageous T cell and cytokine release 
phenotype, which make this an interesting candidate for future clinical applications. 
Introduction 
The unprecedented therapeutic efficacy of CAR T cells in previously refractory blood cancers 
is considered to be one of the major breakthroughs in cancer immunotherapy, culminating in 
the recent market approvals by the Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) for two CAR T cell products (1–7). While CAR therapies have now 
achieved public recognition, their development and the quest for optimal CAR design has been 
a multistep process stretching over several decades. Ever since their initial description in 1989 
by Eshhar et al. (8), the receptors have evolved from a two-chimeric-TCR chain architecture to 
a one-protein design. This design commonly incorporates a single-chain variable fragment 
(scFv) of a given antibody as the antigen binding moiety, an extracellular spacer and a 
transmembrane region as structural features, as well as signal transduction units for T cell 
activation. Originally, the spacer domain was introduced into the CAR framework as an inert 
building block to allow the antigen binding moiety to extend beyond the T cell's glycocalyx and 
improve antigen accessibility (9). Following this assumption, a plethora of spacer regions were 
designed simultaneously ranging from the immunoglobulin (Ig) domains of the crystallizable 
fragments (Fc) of antibodies to extracellular domains of CD8α, CD28, the TCRβ chain or 
NKG2D (10–16) and were applied without comparative analyses. However, already very early 
on, Patel and colleagues provided the scientific proof that the spacer region can be of paramount 
importance for the receptor function and affects its expression, surface stability through the 
turnover rate, and signal transduction (17). More recent accumulating research has further been 
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showing that in addition to the nature of the spacer, effective antigen recognition depends on 
the functional interplay between the spatial localization of the target epitope and the CAR 
spacer length (18–20). For instance, membrane-distal epitopes were shown to most efficiently 
trigger CARs with short spacers, while membrane-proximal epitopes required receptors with 
extended spacer domains to elicit accurate effector function, in this way emphasizing the 
biological requirement of optimal T cell-target cell distance (18–22). Thus, the design of CARs 
against novel antigens needs to consider both the epitope position within the target antigen as 
well as the nature and length of the spacer region and customize these variables accordingly. 
The use of Ig-derived spacers is particularly attractive as it provides the opportunity to modulate 
the spacer length into long (CH2-CH3 domain), medium (CH3) and short (hinge only) 
structures, while retaining the nature of the parent protein. However, Ig-derived spacers have 
faced various complications during their development. In particular, off-target activation, CAR 
T cell sequestration in the lung, tonic signaling and activation-induced cell death (AICD) have 
been described leading to only a limited T cell persistence (23–26). Although these effects could 
be abrogated by mutating the amino acid sequence essential for FcR binding (23, 25, 27), it 
needs to be taken into consideration that these experiments were conducted in 
immunosuppressed NSG mice and whether FcR binding can be entirely eliminated in humans 
remains unclear. Of note, several clinical studies that used IgG-derived spacers described only 
limited anti-tumor efficacy and low CAR T cell persistence (28–31) while others are showing 
some promising clinical responses (32–34). Interestingly, the first commercially available CAR 
T cell-based therapies use CD28 (Yescarta) and CD8 (Kymriah) derived spacer domains. 
Taking into account the shortage of well-described long spacer domains with a favorable 
functionality profile, we endeavored to develop a novel long spacer for membrane-proximal 
epitopes, which naturally lacks an FcR binding domain. Based on the postulated spatial 
requirements between CARs and their target antigens, we anticipated finding a CAR spacer 
construct whose functionality against membrane-proximal epitopes extends beyond that of a 
CD8α spacer CAR. Hence, we generated novel CAR spacers and analyzed their efficacy side-
by-side to the cognate CD8α spacer counterpart – a comparison that has not been extensively 
undertaken thus far. The design of the novel spacers was based on the sialic acid binding Ig-
like lectin (Siglec) receptor family, whose members are broadly expressed on various immune 
cells (35, 36). Structurally, each receptor member is composed of an N-terminal Ig-like V-set 
domain which is involved in sialic acid binding and a defined number of Ig-like C2-set domains 
that serve as a structural spacer and extend the binding moiety away from the plasma membrane. 
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The selection of the Siglec family was inspired by the hypothesis that the incorporation of 
naturally occurring spacer domains into the CAR architecture will preserve the biological 
requirements of a spacer region and minimize unspecific interactions with other cells. 
In this study, we confirm this strategy of using naturally occurring spacer domains by first 
demonstrating, that in a CD20+ lymphoma model a long IgG1 spacer CAR is as functional as 
the CD8α spacer in vitro, but fails to translate its effectiveness in vivo, despite containing the 
earlier reported mutations to abrogate FcR binding (23). Subsequently, we evaluate novel 
spacers derived from the Siglec family of proteins and identify a long alternative spacer derived 
from Siglec-4 that performs with equal efficiency to the CD8α spacer in vitro. Finally, we 
demonstrate in a solid tumor model that the novel Siglec-4 spacer CAR does not exceed, but 
rather matches the CD8α spacer CAR cytotoxic activity in vivo on membrane-proximal targets, 
while maintaining a favorable cell phenotype profile and cytokine release pattern. 
Materials and Methods 
CAR Gene Construction 
Commercial gene synthesis in combination with an optimization algorithm for codon usage in 
humans (ATUM) was used to construct the CAR genes of interest. The CD20-specific scFv was 
derived from the murine monoclonal antibody Leu16 as originally described by Jensen and 
colleagues (37), while the CD66c- and TSPAN8-targeting scFv sequences were derived from 
the antibody clones REA414 (CD66c) and REA443 (TSPAN8) (Miltenyi Biotec). All antigen 
binding domains contained a (G4S)3-linker between the VL and the VH regions. To facilitate 
receptor trafficking to the plasma membrane, a human CD8α leader signaling peptide was 
added N-terminally to the respective scFv sequence. The spacer region downstream of the scFv 
encompassed either the domain for IgG1 hinge-CH2CH3 (234 amino acids), IgG4 hinge-
CH2CH3 (228 amino acids), or CD8α hinge (45 amino acids). To abrogate potential 
interactions of the Fc spacer CARs with FcR-expressing cells, the PELLGG and ISR motives 
in the IgG1 CH2 domain were replaced by the corresponding IgG2 amino acids (23). In the 
case of the IgG4 CH2 domain, the APEFLG sequence was replaced by APPVA from IgG2 and 
an N279Q mutation was introduced to remove glycosylation at this site (25). Spacers derived 
from the Siglec family were designed based on the protein sequences extracted from UniProt 
and the plasma membrane-proximal domains were incorporated into the CAR architecture. 
Thus, the Siglec-3 spacer comprised the amino acids 145–259 of the parent protein with a 
C169S mutation to abrogate unspecific disulfide-bond formation. The Siglec-4 spacer 
contained the amino acids 238–519, the Siglec-7.1 spacer the amino acids 150–353, the Siglec-
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7.2 spacer the amino acids 234–353, and the Siglec-8 spacer the amino acids 241–363 of the 
respective parent protein. All spacers were linked to the transmembrane domain of human 
CD8α, the intracellular domain of 4-1BB, and the CD3ζ signaling domain as derived from 
UniProt. The CAR genes were fused to a Furin-P2A sequence to include co-expression of the 
truncated low affinity nerve growth factor receptor (ΔLNGFR). Transgene expression was 
promoted by the PGK promoter located upstream of the CAR gene. 
Lentiviral Vector Production 
Second generation self-inactivating VSV-G-pseudotyped lentiviral vectors were produced by 
transient transfection of adherent HEK293T cells. One day before transfection, 1.6 × 107 
HEK293T cells were seeded per T175 flask to reach a confluency of 70–90% on the following 
day. Each T175 flask was then transfected with a total of 35 μg plasmid DNA composed of 
pMDG2 (encoding VSV-G), pCMVdR8.74 (encoding gag/pol), and the respective transgene-
encoding transfer vector using MACSfectin reagent (Miltenyi Biotec). All transfection 
reactions were performed with a DNA: MACSfectin ratio of 1:2. Following overnight 
incubation, sodium butyrate was supplied at a final concentration of 10 mM and at 48 h after 
transfection the medium was collected, cleared by centrifugation at 300× g and 4°C for 5 min 
and filtered through 0.45 μm-pore-size PVDF filters. Concentration of the viral stock was 
performed by centrifugation at 4°C and 4,000 × g for 24 h. Pellets containing lentiviral vector 
were air-dried and resuspended at a 100-fold concentration with 4°C cold PBS. Lentiviral vector 
aliquots were stored at −80°C. 
Generation of CAR T Cells 
Automated CAR T Cell Generation 
The CliniMACS Prodigy® TCT (T cell transduction) application was used for the automated 
manufacturing of large amounts of gene-modified T cells. Technical features and experimental 
procedures have previously been described in detail (38, 39). In brief, T cells were obtained 
from non-mobilized leukapheresis from healthy anonymous donors (University Hospital 
Cologne or the German Red Cross Ulm) and were typically processed 24–48 h after collection. 
Transduced and enriched CAR T cells were finally formulated and harvested in Composol® 
solution (Fresenius Kabi), supplemented with 2.5% human serum albumin (Grifols). For quality 
assurance, the transduction efficiency and T cell phenotype was determined using a 
MACSQuant Analyzer 10 (Miltenyi Biotec) after the TCT process. Transduction efficiency 
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were determined by flow cytometry on days 5 and 12 of the TCT process using a flow 
cytometer. 
Manual CAR T Cell Generation 
Buffy coats from healthy anonymous donors were obtained from the German Red Cross 
Dortmund. Peripheral blood mononuclear cells (PBMCs) were then isolated from buffy coats 
by density gradient centrifugation. T cells were purified from PBMCs applying the Pan T Cell 
Isolation Kit, human (Miltenyi Biotec) and activated in TexMACS™ Medium (Miltenyi 
Biotec) supplemented with T Cell TransAct™, human (Miltenyi Biotec) and 100 IU/ml of 
recombinant Human IL-2 IS, research grade (Miltenyi Biotec). T cells were transduced 24 h 
after activation using VSV-G pseudotyped lentiviral particles. 3 days post activation, T Cell 
TransAct™, human and excess viral vector were removed and T cells were cultured in 
TexMACS™ Medium only supplemented with IL-2. T cells were expanded for 12 days and 
used directly for in vitro assays or frozen in TexMACS™ Medium containing 10% DMSO for 
later in vivo use. Frozen T cells that were used for in vivo testing were thawed 24 h before 
injection and cultivated at 37°C in TexMACS™ Medium without further supplements. 
Target Cell Lines 
HEK293T, JeKo-1, Raji and AsPC1 cells were obtained from ATCC and cultured as 
recommended. Raji cells were transduced with a ffLuc cassette for in vivo detection and AsPC1 
cells were transduced with a eGFP/ffLuc cassette for in vitro and in vivo detection. To validate 
authenticity of the cell lines used, we used the Human STR Profiling Cell Authentication 
Service (ATCC). 
Flow Cytometry 
Antibodies specific for anti-human CD62L, CD45RO, CD95, CD271 (LNGFR), CD107a, 
TNF-α, CD223 (LAG3), CD279 (PD1), CD366 (TIM3), CD137 (4-1BB), CD4, CD8, CD3 
were monoclonal recombinant antibodies (Miltenyi Biotec). For anti-CD20 CAR detection the 
CD20 CAR Detection Reagent (Miltenyi Biotec) was used. Staining of Miltenyi Biotec 
antibodies was performed according to the supplier's instructions. For direct CAR detection of 
CD66c and TSPAN8 specific CARs a sequential staining was used. First, samples were 
incubated with polyclonal Fab specific anti-mouse IgG antibodies produced in goat (Merck) at 
concentrations of 10 μg/ml for 30 min at 4°C. Samples were washed and then incubated with 
polyclonal anti-goat IgG antibodies produced in chicken (Thermo Fisher) at concentrations of 
10 μg/ml for 30 min at 4°C. Stained samples were measured on a MACSQuant® Analyzer 8 or 
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MACSQuant Analyzer 10 (Miltenyi Biotec) and analyzed using the MACSQuantify™ 
Software. 
In vitro Functional Assays 
With JeKo-1 Target Cells 
1 × 105 JeKo-1 and 1 × 105 CAR T cells were co-cultured in TexMACS™ Medium (Miltenyi 
Biotec) for 24 h in 96-well round bottom plates. Supernatants were collected at the endpoint 
and used to detect the cytokines released by anti-CD20 CAR T cells using the MACSPlex 
Cytokine 12 Kit (Miltenyi Biotec) with the four selected human cytokines IFN-γ, IL-2, TNF-α 
and GM-CSF, according to the manufacturer's instructions. The cytolytic activity of the 
engineered T cells was evaluated by using 1 × 104 CD20+ JeKo-1 cells labeled with 1 μM 
CellTraceTM Violet (Life Technologies), as target cells. Effector and target cells were co-
cultured for 24 h at the indicated ratios (E:T) in 96-well round bottom plates. Detection of the 
specific lysis was performed by quantitation of Violet dye labeled target cells using a 
MACSQuant Analyzer 8 (Miltenyi Biotec). Mock-transduced T cells were used as control at 
the same effector-to-target ratios. 
With Raji Cells 
2 × 105 CAR T cells were incubated with 2 × 105 CD20+ Raji cells in 200 μl TexMACS™ 
Medium at 37°C. In addition, the medium was supplemented with 20 μl of a CD107a specific 
antibody. After 1 h of incubation the protein transport inhibitors Monensin and Brefeldin A 
(BD Biosiences) were added as recommended for 4 h. After this incubation period, cells were 
washed and first surface stained with LNGFR specific antibodies to label transduced T cells 
and subsequently intracellularly stained for TNF-α using the Inside Stain Kit and a TNF-α 
specific antibody (all Miltenyi Biotec). Cells were then measured by flow cytometry. For TIM3, 
LAG3 and PD1 detection 1 × 105 CAR T cells were inoculated with 2 × 105 CD20+ Raji cells 
in 200 μl TexMACS™ Medium at 37°C for 24 h. Subsequently T cells were stained and 
analyzed by flow cytometry. 
For functionality assays in the presence of NSG macrophages, 2 × 105 CAR T cells were 
incubated in a 1:1:1 ratio with Raji target cells and macrophages derived from a peritoneal 
lavage. The assay was performed in the presence or absence of murine FcR-blocking reagent. 
After 24 h of incubation, detection of the specific lysis was performed by quantitation of Violet 
dye labeled target cells via flow cytometry using a MACSQuant Analyzer 8 (Miltenyi Biotec). 
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With AsPC1 Cells 
GFP+/Luc+ AsPC1 target cells were inoculated in 96-well plates at 2.5 × 104 cells per well in 
TexMACS™ Medium. CAR T cells or untransduced Mock T cells were added with at an E:T 
ratio of 2:1. The amount of T cells in the Mock control was adjusted to the number of total T 
cells in the CAR group with the highest total cell count. Cytotoxicity was measurement as the 
decrease of green surface area as assessed by the IncuCyte® S3 Live-Cell Analysis System 
(Sartorius). Measured values were normalized to the start of the experiment. After 24 h a 
supernatant sample was taken for cytokine measurements using the MACSPlex Cytokine 12 
Kit. At the end of the experiment expression of LAG3, PD1, and 4-1BB were measured using 
a MACSQuant Analyzer 8 (Miltenyi Biotec). Specific endpoint killing was calculated from the 
green surface area values with the following formula: 
specific killing [%]= 100−(100 ∗ green area Mockgreen area CAR ). 
In vivo Assays 
Experiments involving animal handling were approved by the Governmental Review 
Committee on Animal Care in NRW, Germany and performed according to guidelines and 
regulations (Landesamt für Natur, Umwelt and Verbraucherschutz NRW, Approval number 84-
02.04.2015.A168 and Approval number 84-02.04.2017.A021). 
Raji lymphoma were established by tail vein injection of 5 × 105 Raji Luc+ cells. After 7 days, 
1 × 106 CAR T cells or Mock GFP-transduced T cells, adjusted to the total amount of T cells 
according to transduction efficiency of the CARs, were infused intravenously. 
For AsPC1 GFP+/Luc+ cell line derived tumors 1 × 106 cells were injected subcutaneously in 
the right flank of NOD SCID gamma (NSG; NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice 
(Jackson Laboratory, provided by Charles River). When tumors reached a size of 25 mm2, 5 × 
106 CAR T cells were injected into the tail vein. The amount of injected untransduced Mock T 
cells was adjusted to the number of total T cells in the CAR group with the highest total cell 
count. 
Therapeutic response was measured longitudinally using the IVIS Lumina in vivo imaging 
system (PerkinElmer) after intraperitoneal injection of 100 μL (30 mg/mL) D-Luciferin (for 
Raji studies: XenoLight Rediject D-Luciferin Ultra (PerkinElmer). For AsPc1 studies: 
Potassium Salt, LUCK-2G, GoldBio) and additionally by manual caliper measurement for 
pancreatic tumors. All measures to secure the well-being of mice were executed following the 
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relevant animal use guidelines and ethical regulations. Upon reaching the endpoint (weight loss 
of >19%, paralysis, stress score of >20 or end-point of the experiment, Day 20 for the 
lymphoma model and Day 29 for the pancreatic model), animals were euthanized according to 
guidelines and post-mortem analysis was performed in order to determine tumor burden, 
persistence and killing of the different CAR T cell constructs. In particular blood, bone marrow 
and spleen were subjected to flow cytometric analysis. Therefore, spleen was dissociated using 
the gentleMACS™ Octo Dissociator with Heaters according to the manufacturers protocol 
(Miltenyi Biotec) and bone marrow was extracted from the femurs and tibias of mice by cutting 
off the epiphyses of the bones and rinsing the inner fragments. The cell suspensions were 
filtered through a 70 μm pore size MACS SmartStrainer (Miltenyi Biotec) and following red 
blood cell lysis on blood, bone marrow and spleen single cell suspensions using Red Blood Cell 
Lysis Solution (Miltenyi Biotec), samples were stained and analysis was conducted on a 
MACSQuant Analyzer 8. 
Statistics 
Unless otherwise specified, all graphical error bars represent standard error of the mean. 
Statistical comparisons between more than two groups were conducted by One-way ANOVA 
with p < 0.05 using GraphPad Prism 7. To facilitate the statistical overview of the in vivo 
experiments, the significance analyses were organized in a pairwise significance matrix (PSM) 
where each box represents a comparison between two groups, as shown by Al Rawashdeh et 
al. (40). The order, in which the groups were compared, is illustrated in Figures S1, S4. 
Significant differences between two comparing groups are defined by a green box, while 
insignificant differences by a red box. 
Results 
CD20 Specific CD8α and IgG1 CH2-CH3 Spacer CARs Exhibit Comparable in vitro Activity 
During pre-clinical development of a CD20 directed CAR candidate (39) we also evaluated a 
number of different CAR configurations (Figure 1A). We used an scFv derived from the Leu16 
monoclonal antibody (30, 41), binding to the large extracellular loop of CD20 (42). This loop 
is only 47 amino acids long, which is why we hypothesized it would be more effectively 
targeted with a flexible CD8α or long IgG spacer. We generated two second generation CAR 
constructs, that comprised a CD8α transmembrane domain, a 4-1BB co-stimulatory domain and 
a CD3ζ main activator domain. Both bind CD20 via the Leu16 derived scFv in a VH-VL 
orientation and only differed in the spacer domain. The CD20_hl_IgG1 CAR comprises an 
IgG1 CH2-CH3 spacer while the CD20_hl_CD8 CAR possesses a CD8α spacer. The PELLGG 
87 
 
and ISR motif of the IgG1 CH2-CH3 spacer were replaced by the corresponding IgG2 amino 
acids to reduce Fcγ-Receptor binding, as described previously (23). To assess whether the order 
of binding domains in the scFv also can play a role in CAR function, we constructed a CD8α 
spacer CAR with swapped scFv orientation (CD20_lh_CD8). We generated CD20 specific 
CAR T cells by genetically modifying CD3/CD28 polyclonally activated T cells with lentiviral 
vectors in a fully automated manner in a closed system using the CliniMACS Prodigy® as 
described previously (39). At the end of the manufacturing on day 12, similar T cell phenotypes 
were obtained for the samples modified with the different CAR constructs and the untransduced 
Mock control (Figure 1B). More than 80% of T cells had a memory phenotype (central memory 
T cell (TCM) and stem cell memory T cell (TSCM) as defined by their phenotypes being 
CD62L+/CD45RO+/CD95+ and CD62L+/CD45RO−/CD95+, respectively). Also, the three 
constructs demonstrated comparable functionality in terms of cytokine release (Figure 1C) and 





Figure 1. CD20 specific CAR T cells with short CD8α and long IgG1 CH2-CH3 spacers show similar in vitro 
functionality. (A) Structure of the three CD20 CAR constructs. (B) T cell phenotypes in the CD4/CD8 enriched 
fraction on d0, d5, and d12 of the automated T cell transduction process by flow cytometry. (C) GM-CSF, IFN-γ, 
IL-2 and TNF-α production after 24 h co-culture of CD20 CAR T cells with CD20+ JeKo-1 target cells at 1:1 
effector to target ratio analyzed by flow cytometry. n = 3. (D) Cytolytic activity of the engineered CAR T cells. 
Effector CAR T cells and target-positive JeKo-1 target cells were co-cultured for 24 h at the indicated ratios (E:T). 





CD8α and IgG1 CH2-CH3 Spacer CARs Differ in Their in vivo Performance 
Having assessed the in vitro activity, we next analyzed the same lentivirally modified T cells in 
a pre-clinical NSG mouse model. 5 × 105 CD20+ Raji cells, which were modified to 
constitutively express luciferase, were injected into the tail vein of each mouse. Seven days 
later, 1 × 106 CD20 specific CAR T cells or GFP transduced Mock T cells (Figure 2A) were 
also applied intravenously. Tumor burden was monitored longitudinally over 3 weeks by non-
invasive bioluminescent imaging (BLI) of tumor cells in vivo. Neither the Mock treated group 
nor mice treated with the IgG1 spacer CAR showed any control of tumor growth compared to 
the untreated group, and the animals in these groups were sacrificed according to the ethical 
code on day 17 and day 15, respectively (Figure 2B). On the other hand, significant therapeutic 
responses were achieved by the CD20_hl_CD8 and CD20_lh_CD8 CAR T cells (Figures 
2B,D). Both groups exhibited a reduced tumor growth 6 days post T cell injection. While the 
CD20_hl_CD8 CAR T cells reached background fluorescence on day 13, CAR T cells equipped 
with the same CAR but with the scFv in the converse orientation needed longer to reduce tumor 
burden and did not reach background levels until the end of the experiment. This difference 
between the scFv variants could be attributed to a single mouse having remnants of tumor 
present in the jawbone, which in our experience is difficult to treat and possibly inaccessible to 
CAR T cells. We verified that the scFv orientation indeed had only a minor influence by 
repeating the experiment with the CD8α spacer CARs with the different scFv orientations using 
a different donor (Figures 2C,E). Again, both groups of CAR-modified T cells were effective 
in rapidly controlling the tumor growth, with no significant difference being observed between 
the different scFv orientations. Ex vivo analysis of spleen, bone marrow and blood at the end 
of the study showed no detectable IgG1 spacer CAR T cells in the treated mice while CAR T 
cells with the CD8α spacer could be readily detected, implying a reduced in vivo persistence or 




Figure 2. CD20 specific CAR T cells with an IgG1 spacer domain fail to exhibit in vivo efficacy. (A) Overview 
of the study workflows. (B) Tumor burden change over time in mice treated with anti-CD20 IgG1 CH2-CH3 and 
CD8α spacer CAR T cells from one donor. n = 5/group. PSM p < 0.05 (green) [one-way ANOVA]. (C) Tumor 
burden change over time in presence of the two different CD8α CAR constructs with T cells from a second donor. 
n = 6/group. PSM p < 0.05 (green) [one-way ANOVA]. (D) Representative in vivo bioluminescence images of 
tumor bearing mice from (B). Images are arranged according to the treatment group and time after CAR T cell 
injection. T cells were generated from one donor. Scale factor: min: 5 × 106, max: 5 × 108 p/s. (E) Representative 
in vivo bioluminescence images of tumor bearing mice from (C). Images are arranged according to the treatment 
group and time after CAR T cell injection. T cells were generated from a second donor. Scale factor: min: 5 × 106, 
max: 5 × 108 p/s. 
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These findings were in line with earlier results of other groups, showing reduced in vivo efficacy 
of full length IgG family spacers (25, 27). These groups mutated FcR binding sites or developed 
other solutions in order to decrease off-target binding of the T cell, which we were also able to 
confirm in an in vitro assay using mouse macrophages (Figure S3), but it is unclear whether all 
potential off-target binding has been abrogated as binding to other lower affinity FcγRs may be 
retained (25). 
Construction and Characterization of a New Family of CAR Spacers 
These findings motivated us to develop a new class of CAR spacer regions that naturally lack 
FcR binding sites. In this context we identified the Sialic acid-binding immunoglobulin-type 
lectin (Siglec) family whose members are expressed on various immune cells and incorporate 
Ig-like domains in their receptor architecture (43, 44). More specifically, while the membrane 
distal sialic acid binding Ig-like V-set domain is positioned N-terminally, the more C-terminally 
located Ig-like C2-set domains, which vary in number, serve as spacer regions. Based on 
previous reports describing that CAR T cell activation can be optimized according to the epitope 
location and spacer length, we selected one, two or three C2-set domains derived from Siglec-
3, -4, -7, or -8 for spacer design (Figure 3). 
 




To confirm correct translation and surface expression of the constructs, bicistronic lentiviral 
expression vectors were generated with a downstream ΔLNGFR gene linked to the CAR by a 
P2A sequence (Figure 4A). After transfection of the DNA constructs into HEK293T cells, 
detection of the reporter protein ΔLNGFR confirmed successful transcription and translation of 
the CAR cassette, while direct staining of the CAR with a CD20 CAR detection reagent (PE) 
visualized surface expression of the CAR constructs. All constructs showed both ΔLNGFR and 
CAR expression in >80% of HEK293T cells (Figure 4B). Subsequently, we transduced primary 
T cells with lentiviral vectors and assessed the CAR expression 6 days post transduction (Figure 
4C). The ΔLNGFR reporter protein was expressed in all cases demonstrating effective lentiviral 
transduction of the T cells and translation of the expression cassette (range 46–75% LNGFR+ 
T cells). However, while three CAR constructs showed CAR expression levels comparable to 
the CD8α spacer CAR control, no CD20_hl_Sig7.1 CAR expression was detectable and the 
CD20_hl_Sig3 CAR was expressed on only 5% of the T cells. Based on these results, we 




Figure 4. In vitro evaluation of novel CD20 specific Siglec spacer CAR T cells. (A) Modular structure of the 
CD20 CAR constructs with the Siglec spacers and extracellular domain comparison of the CAR constructs. (B) 
Expression analysis of the CAR constructs in transiently transfected HEK293T cells 24 h post transfection and 
(C) in transduced T cells from two donors 6 days post transduction. LNGFR and CAR expression were evaluated 
by flow cytometry. (D,E) Siglec spacer CAR T cells were cocultured with Raji or HEK293T cells for 5 h at a ratio 
of 1:1 and T cell expression of CD107a (D) and intracellular TNF-α (E) were analyzed by flow cytometry. (F) 
The frequency of TIM3, LAG3, and PD1 triple positive CAR T cells was analyzed after 24 h co-culture at a 1:2 
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ratio of CAR T cells to Raji or HEK293T cells by flow cytometry. CAR T cells alone were also cultured in order 
to exclude unspecific activation. n = 3. Error bars, mean ± SD. ns > 0.05, **p < 0.01, and ****p < 0.0001 [one-
way ANOVA, CAR T + Raji compared to Untreated (UnTd)]. 
Siglec-4 Spacer Shows Comparable in vitro Functionality To CD8α Spacer in a CD20 CAR 
Model 
Next, we investigated the cytotoxic potential of the novel constructs. We co-cultured CAR T 
cells for 5 h with CD20+ Raji cells or CD20− HEK293T cells at an E:T ratio of 1:1. Effector 
function was assessed by determining degranulation and intracellular detection of the cytokine 
TNF-α in the transduced cells (gated on ΔLNGFR expression). Only CAR T cells co-cultured 
with CD20+ target cells showed significant degranulation (Figure 4D). Strongest degranulation 
could be observed for the CD8α and Siglec-4 spacer variants with around 35% of CD107α 
positive cells. The Siglec-7.2 spacer CAR produced an intermediate amount of CD107α at 20% 
positive cells and the Siglec-8 variant had the lowest degranulation with only 10% positive cells 
but still more than the negative controls (Figure 4D). Similar to the degranulation analysis, the 
proportion of ΔLNGFR+/TNF-α+ cells was also highest in CD8α spacer CAR T cells (Figure 
4E; 31%) but the CD20_hl_Sig4 CARs only displayed 18% of TNF-α positive cells, followed 
by Siglec-7.2 and Siglec-8 spacer CARs. Again, no unspecific activation could be observed in 
the controls. 
We also assessed the activation state of the modified T cells by analyzing TIM3, LAG3, and 
PD1 surface expression. CD20+ Raji cells were co-cultured with CAR T cells for 24 h at an E:T 
ratio of 1:2. The CD8α and Siglec-4 spacer CAR modified T cells contained the largest fraction 
of TIM3/LAG3/PD1 triple positive cells (Figure 4F). As the Siglec-7.2 and Siglec-8 spacer 
CAR T cells displayed lower degranulation and upregulation of activation markers after antigen 
engagement throughout these in vitro experiments, we decided to investigate only the Siglec-4 
spacer in more detail. 
The Siglec-4 Spacer CAR Displays High Functional Potency Against Membrane-Proximal 
Targets 
In our CD20+ Raji lymphoma model the Siglec-4 spacer CAR demonstrated a comparable in 
vitro functionality to the CD8α spacer CAR. As described above the Leu16 epitope is very 
proximal to the target cell membrane, making it more susceptible for engagement with long 
spacer CARs. From the CAR variants that could be efficiently expressed in T cells, the Siglec-
4 spacer was the only spacer with three C2-set Ig domains, agreeing with previous work that 
long spacers are excellent for targeting “short,” membrane-proximal targets. To verify this 
hypothesis and to prove the robustness of the Siglec-4 spacer functionality, we assessed the 
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Siglec-4 spacer CAR in an additional solid tumor model of pancreatic ductal adenocarcinoma 
(PDAC). We have recently identified CD66c and TSPAN8 as novel target candidates for 
cellular treatment of PDAC (Schäfer et al. manuscript under revision). These two target 
molecules are especially suitable for investigating our novel long spacer, as the scFv binding 
epitopes differ greatly in terms of membrane proximity. 
TSPAN8 has two extracellular loops extending from the membrane that span 24 and 96 amino 
acids, respectively, the larger having two interconnecting disulfide bonds. Thus, the whole 
protein is very membrane proximal. On the other hand, CD66c is a glycophosphatidylinositol 
anchored protein and consists of two C2-set domains and one V-set domain. In consequence it 
extends further into the extracellular space compared to TSPAN8. In addition, the epitope of 
the aCD66c scFv is localized on the outer N terminal V-set domain. In summary, TSPAN8 can 
be considered a membrane proximal target, while CD66c is a membrane distal target. 
We exchanged the Leu16 scFv from our CD20_hl_Sig4 CAR with the CD66c and TSPAN8 
specific scFvs that were previously identified (Figure 5A) (Schäfer et al. manuscript under 
revision). Additionally, we incorporated in our experiments CD66c and TSPAN8 specific 
CD8α spacer CARs and a TSPAN8 specific IgG4 CH2-CH3 spacer CAR, which contained a 
4/2 NQ mutation in the CH2 domain as well as a S → P substitution which has been reported 




Figure 5. In vitro comparison of T cells transduced with TSPAN8 and CD66c CAR constructs, incorporating 
different spacer domains. (A) Structure of the TSPAN8 and CD66c CAR constructs with the Siglec spacers and 
extracellular domain comparison of the CAR constructs and target molecules. (B) Cytolytic kinetics and specific 
endpoint killing of AsPC1 target cells incubated with CAR T cells and Mock T cells from three different donors 
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in effector to target ratios of 2:1. n = 6. (C) Frequency of 4-1BB, LAG3 and PD1 positive CAR T cells was 
analyzed at the end of the cytolytic evaluation with AsPC1 cells by flow cytometry. (D) GM-CSF, IFN-γ, IL-2 
and TNF-α production after 24 h of co-culture of TSPAN8 or CD66c CAR T cells with AsPC1 cells from one 
donor assessed by flow cytometry. n = 2. Data from (B–D) were taken from the same experiment. Shown is the 
mean ± SD. ns > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 [one-way ANOVA, multiple 
comparisons]. 
CD66c+/TSPAN8+ AsPC1 PDAC cells that were additionally modified to express GFP and 
luciferase were co-cultivated with CAR T cells specific for CD66c and TSPAN8 at an E:T ratio 
of 2:1 and analyzed using a fluorescent live cell analysis system. We assessed cytotoxicity as a 
decrease in green fluorescence surface area normalized to 2 h after co-inoculation. After 48 h, 
a supernatant sample was taken for cytokine quantitation while activation markers were 
measured at the end of the experiment (132 h). 
Both, the CD66c_lh_Siglec-4 CAR T cells, as well as the untransduced control T cells showed 
no specific killing of target cells, while the CD66c_lh_CD8 CAR showed a specific endpoint 
killing of 42%, (Figure 5B). On the other hand, when targeting the membrane proximal 
TSPAN8, the Siglec-4 spacer CAR T cells showed a similar killing to that of the 
TSPAN8_hl_CD8α CAR T cells approaching 60% endpoint killing. In contrast, CAR T cells 
modified with a TSPAN8 CAR with the alternative long IgG4 CH2-CH3 spacer exhibited only 
40% killing at the end of the experiment, showing the weakest cytotoxicity of all tested 
TSPAN8 CAR T cells. The CD66c_lh_Sig4 CAR T cells, which showed no cytotoxicity, also 
expressed no activation markers (Figure 5C). The strongest upregulation of activation markers 
4-1BB, LAG3 and PD-1 was observed in TSPAN8_hl_CD8α CAR T cells. Interestingly, the 
TSPAN8 specific Siglec-4 CAR T cells displayed a lower expression of activation markers, 
even though the cytotoxicity equaled that of the CD8α spacer CAR T cells. This difference 
between the CD8α and the Siglec-4 spacer CAR T cells was even more striking at the cytokine 
level (Figure 5D). The TSPAN8_hl_CD8 CAR T cells released markedly higher levels of 
cytokines than the other CAR T cells. The TSPAN8_hl_Sig4 CAR T cells secreted cytokines 
at levels more similar to CD66c_lh_CD8 and TSPAN8_hl_IgG4 CAR T cells, which was very 
surprising, with regard to the same observed cytotoxicity as the TSPAN8 CD8α CAR T cells. 
The Siglec-4 Spacer Is Highly Efficacious in an in vivo PDAC Model 
Finally, we investigated the functionality of the three TSPAN8 specific CAR constructs in vivo 
in a pre-clinical PDAC tumor model. 1 × 106 AsPC1 eGFP+/Luc+ cells were injected 
subcutaneously in NSG mice. Tumor growth was measured non-invasively by BLI imaging and 
furthermore assessed by physical caliper measurement. When the first tumors reached a 
diameter of 25 mm2, treatment groups were randomized according to the BLI signal and tumor 
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size, and treatment was started by i.v. injection of 5 × 106 CAR T or untransduced Mock T cells 
(Figure 6A). Untransduced T cells did not display a therapeutic benefit over the untreated group 
(Figure 6B). All mice from these two groups had to be sacrificed before the end of the 
experiment as tumor ulcerations began to become established. The therapeutic effect for the 
CD8α and Siglec-4 CARs became apparent in BLI measurements from day 6 onwards. The 
tumor burden within the groups treated with the CD8α and Siglec-4 spacer CARs decreased in 
a comparable manner and reached baseline by the end of the experiment 29 days after T cell 
injection. At the same time, tumor growth was controlled by the IgG4 CH2-CH3 spacer group, 
but there was no tumor clearance as seen with the other groups. Persistence of CAR T cells 
could be demonstrated in the spleens of all CAR T cell treated groups with the highest amounts 
found in the CD8α spacer CAR and Siglec-4 spacer CAR groups (Figure 6C). A markedly 
lower amount of CAR T cells could be recovered from the IgG4 spacer CAR group. 
Interestingly, when the phenotype of the human T cells was examined the proportion of TCM 
was twice as high in CD4 and CD8 CAR T cells of the Siglec-4 spacer CAR group as compared 






Figure 6. The TSPAN8 specific Siglec-4 spacer CAR T cells exhibit the same anti-tumor efficacy as the 
CD8α spacer CAR T cells, while retaining a more memory-like phenotype. (A) Overview of the study 
workflow. (B) Tumor burden and change in tumor size over time after TSPAN8 CAR T cell infusion. Untreated 
and Mock T cell treated animals served as controls, T cells from one donor were used. IgG4: n = 5; Sig4 and 
CD8α: n = 4. PSM p < 0.05 (green) [one-way ANOVA, multiple comparisons]. (C) Total number of CAR positive 
T cells recovered from spleens of TSPAN8 CAR-treated animals at the end of the experiment calculated after flow 
cytometric analysis. IgG4: n = 5; Sig4 and CD8α: n = 4. (D) CD4 and CD8 CAR+ T cell phenotypes in the spleens 
of TSPAN8 CAR-treated animals analyzed at the end of the experiment by flow cytometry. n = 4. 
Discussion 
Despite the largely empirical design of CARs based on the functional principles of an antibody 
and the T cell receptor (TCR), CAR T cell therapies have demonstrated remarkable efficacy in 
the hematological tumor setting. Although a direct comparison of results across CAR T cell-
based clinical trials is difficult due to the various differences in protocols, target antigens, co-
stimulatory signaling, treatment regimen, patient groups and disease burden, the rough trend 
can be observed that those receptors that incorporate a CD8α or CD28 spacer region in their 
architecture display better therapeutical efficacy than those that utilize IgG-based Fc domains 
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(1–7, 28–31). Non-clinical studies investigating this effect suggest that the inferiority of IgG 
spacers is due to the engagement with FcγR-expressing myeloid cells (23) resulting in off-target 
activation of both gene-modified T cells and the respective FcγR+ cells. In parallel, additional 
work has been demonstrating that the exemplary performance of CD8α or CD28 spacer CARs 
is partially also attributed to the epitope location on the targeted antigen CD19 and a number of 
studies have affirmed the postulate that membrane-proximal epitopes are best targeted by long 
spacer modules while membrane-distal epitopes are effectively recognized by CARs 
incorporating short spacer elements (18–22, 45). 
In light of these developments, we identified a shortage of functional CAR spacer modules for 
membrane-proximal epitopes. Taking advantage of the well-described CD20 antigen and the 
membrane-proximal binding epitope of Leu16-derived anti-CD20 scFv (42), we sought to 
characterize the properties of CD8α- vs. IgG-based spacer CARs against CD20 in vivo. To 
avoid unintended cross-activation of CAR- and FcγR-expressing cells in the context of the IgG 
spacer, the amino acid sequence for IgG1-FcγR interactions in the IgG1-CH2 extracellular 
domain of the CAR was replaced by the corresponding IgG2 amino acids as described 
previously (23). However, contrary to reports describing increased anti-tumor activity and CAR 
T cell persistence following modifications in the IgG4 spacer to abrogate FcγR-binding in the 
CAR spacer domain (25, 27), we did not observe any in vivo therapeutic efficacy of IgG1 CAR 
T cells after similar modifications in our study. More specifically, the lack of efficacy was 
accompanied with an inefficient persistence of the gene-modified T cells. These results were in 
stark contrast to the functional capacity of the CD8α CAR T cells which – according to current 
understanding – display a less favorable receptor architecture due to the short spacer region. 
Although it is reasonable to conclude that the introduced mutations into the IgG spacer domain 
may not entirely abrogate FcγR binding, it cannot be ruled out that additional mechanisms are 
in play that sacrifice the therapeutic efficacy. For example, it has already been described that 
murine scFvs and other non-self gene products can elicit HLA-restricted T cell-mediated 
immune responses (3, 46, 47). Thus, the possibility exists that the introduced mutations into the 
Fc region can create immunogenic peptides by the T cell's antigen processing machinery which 
are then presented on the T cell's HLA and render the gene-modified lymphocytes susceptible 
to TCR-triggered fratricidal activity. Therefore, it is to be appreciated that the interplay of CAR 
T cells with their cognate counterparts and the immune system is complex and further work is 
required to understand the full immunogenic potential of CAR molecules. 
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To exclude the possibility of potential immunological barriers elicited by the spacer region, we 
switched our test system to the IgG4 backbone which was previously described to show in vivo 
performance (25, 27) and which has also shown successful translation to the clinic (34). In 
addition, a new set of spacer domains was designed based on the Siglec family whose members 
are expressed throughout the immune system and display evolutionary structural similarities to 
the constant region of immunoglobulins, but lack the inherent ability to interact with FcγRs (35, 
36). To determine systematically the optimal spacer length for the membrane-proximal CD20 
epitope, five Siglec spacer CAR variants were generated incorporating either one, two or three 
Ig domains. Of note, different parent proteins were selected, as different Siglec molecules 
encompass distinct glycosylation patterns which are likely involved in modulating the protein's 
stability, flexibility, spatial architecture etc. and thus may have different effects on the CAR 
molecule. Moreover, in an attempt to maintain the original architecture of the molecule, the 
domains closest to the plasma membrane were selected. Consequently, the Siglec spacer regions 
within the otherwise identical CAR framework encompassed either a 114 amino acid (aa) 
Siglec-3, 119 aa Siglec-7, 127 aa Siglec-8, 203 aa Siglec-7, and 280 aa Siglec-4 spacer domain 
as opposed to the control 45 aa CD8α spacer domain. 
Subsequent expression profiling revealed that not all Siglec spacer-based CARs were efficiently 
expressed on the T cell surface. In particular, Siglec-7.1 and Siglec-3 spacer CARs showed the 
lowest expression efficiency emphasizing the importance of the spacer region not only on the 
receptor's functionality but also on its optimal expression. In fact, Patel and colleagues have 
already described that the CAR spacer domain can affect the receptor's stability and modify its 
turnover rate (17). It is plausible that the glycosylation patterns present in Siglec-7.1 and Siglec-
3 spacer CARs render the receptors less stable, in this way increasing the turnover kinetics and 
a decreased CAR detectability on the cell surface. Another potential reason for the inefficient 
expression of the Siglec-3 spacer CAR may lie in the C169S mutation which was introduced in 
order to abrogate unspecific disulfide bond formation as C169 is involved in an interdomain 
disulfide bond within the parent protein. Moreover, it is possible that the Siglec-3 C2-set 
domain per-se is instable when isolated from the membrane-distal V-set domain. Although a 
splice variant of CD33 has been described, which lacks the N-terminal domain (CD33ΔE2), these 
reports rely on mRNA analyses (48, 49). Protein-based detection using antibodies remains 
controversial, as it is still not clear whether a clone exists that can specifically recognize the 
Siglec-3 C2-set domain (49, 50). Importantly, using lentiviral transduction of His-tagged 
CD33ΔE2, Laszlo and colleagues have shown that the expression of the splice variant is also 
dependent on the cell type (49). In this context, HEK293T exhibited highest transgene 
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expression while hematopoietic cells displayed only low level expression of the truncated 
immune receptor which is in line with our observations on the expression of the Siglec-3 spacer 
CAR (Figures 4B,C). 
In the next series of experiments, the three best expressed Siglec spacer CAR candidates were 
analyzed for their ability to induce T cell effector function upon antigen engagement. Consistent 
with previous reports (17–19, 25, 26, 51), our study provides evidence that the CAR spacer 
region can modulate the effector function of transgenic T cells. Intriguingly, however, we find 
that depending on the effector function analyzed, the functional hierarchy may vary. In 
particular with regard to cytotoxicity, no significant differences between the CD8α spacer (45 
aa in length, no Ig domain) and Siglec-4 spacer (280 aa in length; three Ig domains) CAR can 
be observed while in terms of cytokine secretion the CD8α spacer CAR displays a significant 
dominance over other CAR constructs. Importantly, in addition to the CD20 system, this 
observation was further confirmed in the setting of another membrane-proximal antigen, 
TSPAN8, indicating a common functional feature for membrane-adjacent epitopes. 
It has already been demonstrated in the TCR-context that distinct thresholds exist for the 
cytolytic machinery, the proliferative induction as well as the cytokine production system (52–
56) and emerging work suggests similar principles for CAR-triggered T cells (26). The current 
study further supports this finding and the data obtained indicate that the nature of the spacer 
region can modulate the nature and degree of effector function. An alternative strategy has been 
described by Liu and colleagues (57) and Caruso and colleagues (58) in two independent 
studies, in which they demonstrate the ability of effector function fine-tuning through scFv 
affinity modulation. The clinical impact of such modifications was impressively demonstrated 
by Ghorashian and colleagues, who reported a better overall therapeutic profile of CD19 CAR 
T cell therapies in patients who received lower affinity CARs compared to the commonly used 
FMC63-scFv-based CARs (59). In particular, while the antileukemic activity was retained, the 
CAR T cells displayed an enhanced proliferative capacity and reduced severity of cytokine 
release syndrome (CRS). Though this clearly reveals the effectiveness of such an approach, 
scFv affinity modulation is a laborious undertaking and bears the risk to result in unwanted 
modifications to the target specificity. Therefore, fine tuning the chimeric receptor's spacer 
region provides a time-profitable option with a lower risk profile. More importantly, it further 
allows to create a variety of receptors with a range of signal transduction intensities independent 
of the binding domain. 
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Besides, based on the efficacy data obtained with the CD8α spacer (45 aa) vs. Siglec-4 spacer 
(280 aa) CARs targeting CD20 and TSPAN8, we find that the receptors' cytotoxic efficacy is 
not dominated by the spatial constraints of the CAR and its target epitope. This is significant as 
previous studies reporting such a trend were performed primarily in the context of IgG-derived 
sequences (25, 26, 51) and have not been compared extensively to spacers derived from other 
parental proteins. Thus, our work demonstrates that not only structural and spatial elements in 
CAR T cell:target cell interaction influence a receptor's bioactivity, but also additional factors 
are in play that are not entirely understood or fully considered yet. It is likely that e.g., CAR 
flexibility/rigidity and surface stability may have a greater relevance than previously assumed. 
For instance, Patel and colleagues have shown that the spacer domain can diminish a CAR's 
functionality by increasing its turnover rate (17). Thus, it is important to take into consideration 
that Ig domains as they are present in IgG and Siglec spacer domains display a distinct structural 
folding while the CD8α spacer is derived from a stalk connecting an Ig-like domain with the 
membrane. Attempts to resolve the structure of the CD8α hinge domain were of limited success 
so far, indicating the relative flexibility of this region (60). The Siglec-4 or the IgG spacers are 
missing this flexibility and in this way reduce targetable epitopes to the ones located in 
membrane proximity. 
Another important aspect to be taken into consideration is the tendency of the CD8α stalk region 
to heterodimerize with CD8β, the subunit that contains raft-localizing determinants (61). As 
lipid rafts contain an accumulation of accessory molecules decisive for signal transduction and 
the intracellular CD8β domain has been described to promote association with the two crucial 
players Lck and LAT (62), it is likely that – in the context of cytotoxic T cells – the CD8α 
spacer region is capable of attenuating the effector function threshold by fostering interaction 
with downstream signaling molecules. These effects are absent in IgG- and Siglec-based 
spacers, so that the overall induction of T cell function is likely primarily guided by the number 
of triggered CAR molecules (Figure S5). 
In support of the in vitro data, the Siglec-4 spacer CAR displayed a similar anti-tumor efficacy 
in vivo as the cognate CD8α spacer CAR against TSPAN8 and both therapies were superior to 
the IgG4-based spacer CAR treatment. Taking into account the length of the spacer regions 
(CD8α: 45aa; Siglec-4: 280 aa; IgG4: 228aa), we could not observe any obvious correlation 
with CAR potency and rather identified an intrinsic inferiority of the IgG4 spacer in vivo. 
However, in the context of the TSPAN8 targeting, the modified IgG4 spacer CAR showed a 
much better relative in vivo performance to the CD8α spacer compared to the IgG1 spacer 
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performance in the CD20 study. Indeed, the modified IgG4 spacer (25) has now demonstrated 
good efficacy in ongoing clinical studies (34) indicating that other factors in CAR design such 
as the scFv binding domain, transmembrane domain or the drug product formulation may also 
play a role in in vivo function and T cell persistence. 
Strikingly, however, while the cytotoxic activity was comparable between the CD8α and 
Siglec-4 spacer CARs, we observed a reduced secretion of pro-inflammatory cytokines and an 
attenuated upregulation of activation/exhaustion markers such as 4-1BB, LAG3, and PD1 in 
the Siglec-4 spacer CAR T cells. Moreover, while the proliferative capacity of Siglec-4 CAR T 
cells was slightly lower compared to CD8α spacer CAR T cells, the Siglec-4 CAR-treated mice 
featured a trend toward a higher fraction of TCM phenotype within the CAR T cell cohort which 
is associated with better overall remission and decreased likelihood of relapse in a clinical 
context. 
It is currently widely established that CAR efficacy correlates closely with the development 
and severity of CRS in the clinic, an adverse event whose management has proven challenging 
in the clinical setting. Although tocilizumab and glucocorticoids have been described as 
effective intervention options, finding the right timing for their application represents a big 
hurdle (1, 63). In fact, too early intervention may jeopardize the therapeutic efficacy and 
increase the risk of relapse, while too late intervention bears the risk of CRS-induced multi-
organ failure and irreversible neurotoxicities resulting in a patient's death (1, 3, 5, 7, 64–68). 
Thus, a treatment modality that retains the cytotoxic ability of currently approved CAR T cell 
therapies but attenuates the levels of secreted cytokines may turn engineered T cells not only 
into a reliable and effective, but also a safer platform. Moreover, a concomitant increase of the 
memory phenotype in the CAR T cell cohort of the patient holds promise to further increase 
the therapeutic efficacy while reducing life-threatening side effects. 
Although the phenotype of Siglec-4 CAR modified T cells bodes well for future clinical 
application, what is the potential toxicity profile of this novel spacer structure? The parent 
protein Siglec-4, also known as myelin-associated glycoprotein (MAG), has been reported to 
be exclusively produced by myelinating glial cells such as oligodendrocytes in the central 
nervous system (CNS; 1% of total protein mass) and Schwann cells in the peripheral nervous 
system (PNS; 0.1% of total protein mass) (69, 70). Its specific expression on the innermost 
layer of myelin directly opposite to the axon surface supports its crucial role in the stabilization 
of axon-myelin interactions, the regulation of myelination, and the inhibition of axon 
regeneration after injury (71–73). These effects have been first described to be mediated by the 
105 
 
N-terminal V-set domain of the receptor, as determined by ligand specificity analyses, site-
directed mutagenesis and analogy to the crystal structure of Siglec-1 (74–77). In our evaluation 
of homology studies, we found the protein sequence to be the best conserved among the Siglecs 
and within mammalian species. Indeed, the highest sequence homology was identified to lie 
within the first two N-terminal domains of Siglec-4 (78). Consequently, in order to abrogate 
these interactions, both N-terminal domains were excluded from our CAR spacer design. 
More recent studies, however, suggest that an alternative binding domain exists that interacts 
with the Nogo receptor 1 and 2 (NgR1, NgR2), but not NgR3 (79–82). Deletion analysis 
demonstrated that while the first three Ig-like C2-set domains (amino acids 17-325) of Siglec-
4 are involved in these interactions, C2-set domains 3-5 (amino acids 234-506) as they are 
present in our CAR architecture fail to associate with NgR1 or NgR2 (83) indicating that 
domains 1 and 2 are the major interaction partners. Interestingly, both a soluble and membrane-
bound receptor construct comprising the C2-set domains 3-5 of Siglec-4 (amino acids 234-506) 
are still able to inhibit neurite outgrowth in the CNS, suggesting the existence of an as of yet 
unidentified ligand partner (83, 84). This observation may indicate the potential risk of 
unwanted interactions of the Siglec-4 spacer-based CAR T cells with this unknown binding 
partner. Although the CNS is an immune-privileged organ an intensive infiltration by CAR T 
cells has been shown to occur as a result of blood-brain-barrier (BBB) damage due to strong 
CRS. However, as Siglec-4 spacer CAR T cells appear to produce lower levels of cytokines, 
BBB disruption is expected to be mitigated, in this way minimizing CNS accessibility for CAR 
T cells. 
In support of this hypothesis, despite the high homology between human and rodent Siglec-4 
of 95% at the amino acid level over the entire extracellular domain (85, 86), we did not observe 
any toxicities in the mouse cohort receiving Siglec-4 spacer CAR therapy in our in vivo studies. 
Nevertheless, since - to the best of our knowledge - human-mouse cross-reactivity of Siglec-4 
and its interaction partners has not been determined, these data need to be handled with care 
and further analysis is required to investigate the extent of potential side-effects of Siglec-4 
spacer-based CAR T cells. 
In summary, this study introduces the new class of Siglec CAR spacers, which structurally 
resemble IgG class spacers without their FcγR binding features. The Siglec-4 spacer proved to 
be as efficient as a conventional CD8α spacer in both in vitro and in vivo CAR function, but 
exhibited advantageous traits in terms of the T cell phenotype and CAR T cell cytokine release, 
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which make it an interesting candidate CAR structure to translate into future clinical 
applications. 
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5.1. Target discovery 
CAR T cells do not only harbor great potential for treatment of cancer patients but also represent 
a substantial challenge for physicians and researchers. These highly sensitive cells are able to 
kill almost any cell in the human body to which they are specific for and can persist for several 
months or even years, hence delivering a long-time immunity (Ghorashian et al., 2019). This is 
in stark contrast to small molecule agents or chemotherapies, which in general have half-lives 
of days or hours (Lennernäs et al., 2003). While this extraordinary efficacy and persistence is a 
strong advantage, it can become problematic when directed towards non-tumor cells, making 
the choice of the target antigen of superior importance. Knowing the insufficiencies of 
established PDAC CAR targets, the first objective of this study aimed at identifying novel target 
candidates followed by a characterization of their putative safety profile by analyzing somatic 
tissue expression. 
5.1.1. On-tumor specificity  
Our starting point for this study was the flow cytometric screening of 371 surface antigens on 
a heterogenous set of dissociated tumor samples from human PDAC PDX mouse models with 
15 different mutational backgrounds. Most of the surface antigens identified on cells of the 
xenografts were differentially expressed, mirroring the diversity of PDAC. From this group 
three surface antigens displayed a homogeneous high expression: CD66c, which belongs to the 
protein family of carcinoembryonic antigens (Hammarström, 1999); the tetraspanin protein 
family member TSPAN8 (Charrin et al., 2014) and the glycosylation CLA, which is a 
specialized variant of the surface protein SELPLG (Fuhlbrigge et al., 1997; Ohmori et al., 
2006). The strong expression of these target candidates on PDXs could be corroborated later 
on primary human PDACs. These targets qualify thus for an application on a broader range of 
patients. This may not necessarily be true for CD318, another surface protein also known as 
CDCP1, which was expressed on all of the human tumors investigated by us, but not on all cells 
categorized as tumor cells using flow cytometry and EpCAM as tumor marker. Nonetheless, 
targeting only a subpopulation of a tumor may be enough to elicit cytokine release strong 
enough for an intrinsic immunogenic response (Nemunaitis, 2005).  Furthermore, it has to be 
considered that EpCAM is a general marker for the epithelial linage (Keller et al., 2019). Hence, 
not every EpCAM+ cell is a tumor cell. This combined with an overall lower expression of 
CD318 as compared to the other three targets may lead to the underestimation of its expression 
in this flow based assay. Gating strategy is of critical importance, especially when low 
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expressed markers are investigated (Verschoor et al., 2015). Thus, we verified CD318 
expression on all tumor cells on two additional human PDACs using microscopy as a second 
method. Optical methods have the advantage that structural information of a cell can be used to 
identify tumor cells and are also used in clinical diagnosis (Kleeff et al., 2016).  
We chose this multifaceted set of PDXs in terms of mutational diversity intentionally, as PDAC 
itself has a very heterogenous mutational landscape (Waddell et al., 2015; Witkiewicz et al., 
2015; Bailey et al., 2016). Most of current PDAC CAR targets are only specific for 
subpopulations of patients (Akce et al., 2018), which may be a consequence of the high 
plasticity of PDAC. Hence, we included these diverse PDAC mouse models in order to identify 
targets expressed on the majority of tumors, which is indeed the case for our four targets CLA, 
CD66c, CD318 and TSPAN8.  
Both, the diversity of target models investigated as well as the sheer amount of target candidates 
measured are unique to this study and unprecedented in the context of CAR T cells. Another 
study using a similar experimental design was conducted by Mount and colleagues. However, 
they applied a panel containing only 242 antibodies, on four different patient derived cell lines 
of diffuse intrinsic pontine glioma (Mount et al., 2018). They identified GD2 as most promising 
target but did not perform a subsequent safety analysis, which is in contrast to our study. We 
included a thorough safety assessment and found our targets to have safer expression profiles 
as previous CAR targets as discussed in the next chapter. Other studies comparing a broad set 
of surface antigen expression on a diversity of tumor cells with antibody based methods are 
missing.  
We chose a predefined set of antibodies as investigation basis, as it comes with several benefits 
for subsequent target identification and CAR development. The antigen expression can be 
measured and quantified directly on the protein level, which is in contrast to RNA sequencing 
and proteomics based methods. Also, the subsequent specificity of the CAR T cells remains the 
same as observed in the binding studies, as the CAR binder and the antibody used for discovery 
have the same paratope. These traits simplify subsequent CAR analysis. The fact that the design 
of functional CARs is a rather elaborate process with its own hurdles is exemplified by several 
other studies, which suggested novel CAR target candidates but did not proceed to CAR cloning 
and testing (Orentas et al., 2012; Bosse et al., 2017; Perna et al., 2017). Another inherent 
problem of target discovery using omics based methods is their predictive nature. Algorithms 
have to be applied on the collected data in order to identify transcripts meant for later surface 
expression. Transmembrane domains are highly complex and variable in structure, which make 
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them difficult to define (Koehler Leman et al., 2015; Sezgin et al., 2017). Using transcriptomics 
has gained huge interest as its costs declined and it became easier to use (Timp and Timp, 2020). 
RNA sequencing however is only highlighting the first step from the gene to its final product. 
Until mRNA is translated and a protein reaches the cell surface, a lot of interferences are to be 
expected. Post-translational modifications may take place and the cellular transportation system 
is highly complex, leading to not necessarily correlating mRNA and cell surface protein levels 
(Schwanhäusser et al., 2011; Jiang et al., 2020). In addition, not every algorithm includes target 
identification of the several molecule classes, which can be found on a cell surface. 
Phospholipids, carbohydrates and proteins can all be detected simultaneously using antibodies, 
while for mass spectrometry detection of the several classes the experimental set-up needs to 
be changed (Coman et al., 2016). All these difficulties lead to increasing the chance to include 
false positives. Perna et al. performed proteomic and transcriptomic studies and narrowed down 
the field of candidates for the treatment of AML from 4942 to 24 (Perna et al., 2017). Of these 
24 candidates, the expression of only 9 could be verified on AML patient cells using antibody-
based flow cytometry. This exemplifies that target discovery based on transcriptomic and 
proteomic approaches can lead to valid novel target candidates, but it is crucial to further 
experimentally validate those, while this is already included in antibody-based screening 
methods, as applied in this study. We did not rely on predictive omic workflows and could 
demonstrate the presence of our targets using flow cytometry on PDXs and dissociated human 
tumors, as well as microscopy on human PDACs tissue samples.  
A clear disadvantage of using pre-defined antibody arrays for target discovery is the restriction 
of possible targets to the number and specificities of antibodies contained in the array. While 
our target discovery panel contained almost 400 antibodies, modern mass spectrometry 
methods are able to identify ~3.000 surface proteins (Bausch-Fluck et al., 2018; Jiang et al., 
2020). Our approach had thus a 7.5 times smaller field of potential targets. Moreover, these 
antibodies haven been defined and validated on epitopes already known. This is why we were 
not able to unravel truly novel surface antigens, as CLA, CD66c, CD318 and TSPAN8 are 
already known in other contexts (Fuhlbrigge et al., 1997; Hammarström, 1999; Wortmann et 
al., 2009; Charrin et al., 2014). Using an antibody array nullifies chances of discovering a truly 
novel target, in contrast to omics based approaches.  
5.1.2. Off-tumor safety profiling 
Although maybe the most critical part of CAR T cell therapy, the off-tumor safety evaluation 
of potential target candidates has often been conducted less thoroughly than necessary. Given 
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the known shortcomings and sometimes contradictory predictions of transcriptomic and 
proteomic data, we aimed at combining the information of several databases. In difference to 
previous studies (Bosse et al., 2017; Perna et al., 2017), we tried not to bioinformatically predict 
the absence of CAR target candidates but rather ordered them with respect to the likelihood of 
overall lowest expression. This helped narrowing down the field of target candidates from 50 
to 8, which had to be analyzed by antibody based methods, for the reasons described above, to 
verify absence of the target candidate.  
Of these 8 target candidates being specific to tumor cells as shown by flow cytometry and 
cyclic IF, our off-tumor expression ranking indicated that CLA, CD66c, CD318 and TSPAN8 
had the most restricted expression profiles on healthy tissues. Interestingly, they ranked safer, 
than most of the previously used CAR targets, like HER2 and EGFR. Unsurprisingly, for all 
four target candidates, some restricted off-tumor expression was predicted. In the case of CLA, 
this prediction has to be analyzed carefully. CLA is a glycosylation and the ranking was 
performed using the suspected backbone protein SELPLG (Fuhlbrigge et al., 1997). This might 
not reflect the real expression pattern, which is supposedly more restricted as CLA is only 
present on a subset of SELPLG expressing cells. 
Subsequently, we first aimed to generate functional CAR constructs specific for these four 
candidates, as analysis for clinical applicability is irrelevant, when no functional CAR 
constructs are available. This strategy succeeded, as no functional CLA CARs could be 
generated due to CAR T cell self-recognition, making a continued safety analysis obsolete. We 
screened the remaining three candidates on 17 tissues that have been identified by our 
bioinformatical safety assessment as problematic, such as liver, colon, lung and kidney, using 
cyclic IF and additionally on whole blood using flow cytometry. While CD318 was not 
detectable on almost all tissues, CD66c and TSPAN8 displayed some scattered expression, 
especially in the gastro-intestinal tract. Therefore, further studies should address strategies to 
increase CAR T cell safety as discussed below. This verification step is of utmost importance 
and was not always conducted for some established CAR targets (Katari et al., 2011; Maliar et 
al., 2012; Abate-Daga et al., 2014; Posey et al., 2016), which also has historical reasons.  
Around the millennium change CAR T cell therapy was still infantile and comprehensive 
expression databases were not existent yet (Barrett et al., 2012; Kolesnikov et al., 2014). 
Machines and computers to generate and analyze the huge amount of data that they can do today 
were not available. What was available, were toxicity data from clinically approved antibodies. 
Some of the CAR targeting antigens that are used in current PDAC therapy have been targeted 
125 
 
by antibody therapies before, such as HER2 and EGFR (Hudis, 2007; Martinelli et al., 2009; 
Costa and Czerniecki, 2020). These therapies proofed to be safe. However, CAR T cells as “a 
living drug” have different and hard to control pharmacokinetics and are more powerful than 
antibodies (Szöőr et al., 2020). While low off-tumor expression may be tolerable for antibody 
based therapies due to controllable pharmacokinetics allowing for a therapeutic window, this 
can lead to serious adverse events in case of CAR T cell administration, as exemplified by 
therapies directed to HER2. While the antibody trastuzumab has been in clinical use for years, 
HER2 specific CAR T cell administration lead to a deadly adverse event (Hudis, 2007; Morgan 
et al., 2010). Of note, our off-tumor expression evaluation ranked these targets lower as the 
ones suggested by this study. A meticulous investigation of expression patterns of HER2, as 
well as a holistic CAR functionality testing as conducted for the novel targets CLA, CD318, 
CD66c and TSPAN8 from this study, would have helped to gather a better informed 
understanding of the expression pattern of the target and CAR T cell behavior towards it. As 
response to potential off-tumor toxicities, alternative injection routes (Katz et al., 2015) or fine-
tuned CARs (Caruso et al., 2015) could have been applied. 
When using refined clinical protocols, administration of HER2 specific CAR T cells can be 
save, without severe side effects (Ahmed et al., 2015; Hegde et al., 2017). Apparently, a fine 
interplay between CAR T cell dose, CAR expression and target expression determines a 
therapeutic window that can be exploited (Watanabe et al., 2018). Following this suggestion, 
newer studies implemented methods to determine target overexpression in tumor tissue as 
compared to normal tissue (Orentas et al., 2012; Bosse et al., 2017; Perna et al., 2017). Bosse 
and colleagues defined a log-fold change of RNA expression of above one as sufficient, Orentas 
et al. calculated a T value based on RNA expression that had to be higher than 10 for differential 
expression between diseased and healthy tissue, while Perna et al. categorized expression 
differences in low, medium and high depending on gaussian distribution and distance to the 
standard deviation for mass spectrometry data and transcriptomic databases. While these 
methods may be using arbitrarily chosen thresholds, they are precise in giving relative 
expression differences, which can be used for narrowing down the field of target candidates. 
However, when basal tissue expression is strong already and tumor expression even stronger, 
the difference still has a big margin, but CAR T cells would most likely act on healthy tissues, 
as basal expression is already above the activation threshold. If these differences will be able to 
open up a therapeutic window sufficient for treatment remains unclear. Most important, each 
database has an intrinsic detection limit. This is unproblematic for on-tumor detection, as 
investigators are looking for highly expressed surface molecules. For off-tumor expression 
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evaluation however, it is not clear, if the detection limit of the respective experimental method 
matches the detection threshold of CAR T cells. Thus, also the final step in off-tumor expression 
evaluation should be antibody based binding investigations as conducted in this study. This is 
exemplified by the results of Bosse et al., who found mRNA expression of their target GPC2 
for neuroblastoma only slightly above background in skin and testis, while their IHC analysis 
on 36 healthy human tissues revealed expression on 25% of the tissues (6 weak cytoplasmic, 1 
strong cytoplasmic, 2 weak membrane bound)(Bosse et al., 2017). Also Perna et al. identified 
9 target candidates using transcriptomic and proteomic methods (Perna et al., 2017). Notably, 
they did not include spleen and blood in their analysis and consequently had to eliminate 5 more 
candidates after flow cytometry based measurements revealed their expression on T cells.    
Being aware of this predicament, we decided to first circumvent absolute statements about 
tissue expression. Instead, we prioritized our tumor specific candidates by using several 
databases that derived their data from different experimental methods. Human Protein Atlas 
(Uhlén et al., 2015), GTEx (https://gtexportal.org/), Human Proteome Map (Kim et al., 2014) 
and ProteomicsDB (Wilhelm et al., 2014) offer data from RNA sequencing, proteomics by mass 
spectrometry and antibody based methods, all of them with different advantages and limitations 
as described above. This led finally to an informed understanding of the expression patterns of 
our novel targets in healthy tissues. That this is a valid approach was further underlined, as our 
novel target candidates were higher ranked as targets already under investigation, such as 
CD133, EGFR or HER2, indicating a higher healthy tissue expression for previously known 
targets. 
5.1.4. Adding crucial information by spatial analysis of protein expression on the single cell 
level 
This study together with previous work from others pointed out the importance of antibody 
based validation of predicted target candidates from transcriptomics, proteomics or 
bioinformatical databases (Bosse et al., 2017; Perna et al., 2017; Reinhard et al., 2020). Our 
newly developed cyclic IF device proved to be especially valuable in that regard. While 
traditional IF microscopy is limited to simultaneous staining of up to six conjugates (Lin et al., 
2015), we performed cyclic IF runs, which marked 98 and 107 antigens on the very same tissue 
section, leading to direct verification if an antigen is expressed on the cell surface or not. This 
enabled us to compare a broad range of potential target candidates and analyze their tissue 
specificity and localize their expression to specific cells within the tumors. We confirmed, that 
our target candidates CLA, CD66c, CD318 and TSPAN8 are highly specific to PDAC tumor 
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cells. This was different for target candidates like CD51, CD59 or CD195. They proved to be 
expressed in PDAC tissue samples; however, not on the tumor cells themselves but rather in 
the desmoplastic stroma, disqualifying them for CAR T cell therapy. Future studies may take 
advantage of this multiplexed analysis, as it was conducted in this study. 
Defining the localization of certain target candidates is of special importance in the context of 
off-tumor expression and CAR safety. The bioinformatical databases used in this study do not 
resolve expression profiles to a single cell level, but rather display the average over all cells of 
an organ. Thus, target candidates may be expressed on indispensable organs, but within these 
organs might be restricted to non-vital cell types. This information is lost during bulk analysis. 
For example, our bioinformatical analysis predicted some expression of CD66c in the liver, 
while we could show, that this is a marginal amount of blood cells. Expression was also 
predicted within skin tissue. We could clarify, that this expression is restricted to hair follicle 
cells, which are non-essential. Although a general trend can be observed to conduct research 
more often on single cell levels (Angerer et al., 2017; Marx, 2019), this was not the case for the 
databases used at the time of this study. Analysis of tissues by cyclic IF can fill this gap as 
shown by our results.  
Not only does cyclic IF help to delineate expression on single cell level, but also the polarization 
of a cell can be captured. Here, we demonstrated expression of CD66c in colon epithelium. 
However, CD66c is localized to the luminal part of the colon, making it unlikely to be presented 
to immune cells. Thus, although expressed in colon, CD66c could still be a valid cancer target, 
as it is not reachable for CAR T cells on healthy colon. For CAR T cell therapy this can be 
precious information. As healthy cells express certain markers in a polarized fashion this could 
also be used helping CAR T cells to differentiate between healthy and malignant cells. For 
example, the family member of CD66c, CEA is also expressed to the luminal side of the colon 
(Thistlethwaite et al., 2017). This polarity is lost in desmoplastic cancer cells, enabling CAR T 
cells to target these specifically.  
Ultimately, investigators are enabled to not restrain the number of antigens to be measured on 
rare samples. Especially, healthy tissues are difficult to obtain. During the course of this study, 
we performed a multi-tissue array of 17 non-malignant tissues and investigated the expression 
of CD66c, CD318 and TSPAN8 on each, using cyclic IF. We found a very restricted expression 
of these targets in normal tissue, without using a second slice from any tissue. As the number 
of investigated antigens can be increased, it is a future option to investigate dozens of markers 
on multiple tissues simultaneously. While the measurement of multiple antigens on one tumor 
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sample could help stratifying patients, the measurement of few markers on multiple healthy 
tissues facilitates a simplified drug or biomarker discovery.  
5.2. CAR design 
5.2.1. Safety engineering of CAR T cells 
Even though CLA and CD318 could be targetable by a direct CAR (given a technical method 
for CLA-CAR T cell generation is established), as introduced in this study, somatic tissue 
expression – especially of CD66c and TSPAN8 – raises some concern about their applicability 
as stand-alone targets of conventional CARs and accordingly a strategy to prevent arising 
toxicities should be prepared. Previously, combinatorial CAR engineering strategies have been 
developed to mitigate or completely spare off-tumor toxicities. The idea is that CAR T cells are 
only activated when a target combination is present on the cell. Of course, this combination of 
targets has to be unique to the malignant cell. 
An auspicious combination for this strategy could be the engagement of CLA and CD318 or 
TSPAN8, as these have the most distinct expression patterns. CLA so far has only been reported 
to be expressed leucocyte subsets and high endothelial venules (Fuhlbrigge et al., 1997; Strunk 
et al., 1997; Tu et al., 1999; Yoshino et al., 1999; Dzionek et al., 2000; Tsuchiyama et al., 2002), 
while this study showed very restricted expression of the two other targets with no overlapping 
expression on blood cells. This is in contrast to CD66c, which was markedly expressed on 
neutrophils, therefore bearing the risk of cytotoxic action on neutrophils if CLA is targeted 
together with CD66c. CD318 in combination with TSPAN8 might be a good combination as 
well, although overlapping expression in the colon could elicit damage. Finally, a combination 
of one of the novel target candidates presented here with a target already in clinical 
investigation, such as mesothelin, could be a promising option, too.  
Two approaches to enable these combinatorial targeting are described in the literature. One 
approach relies on the principle of inducing full activation of the CAR T cell only when a 
combination of two target antigens is present on the target cell (Fig. 4). This can be achieved 
by splitting the main- and co-stimulating domains onto two individual CARs. These CARs are 
directed to different antigens, thus the requirement for this system to induce activation is the 
binding of a target combination, uniquely specific to the tumor cells (Fig. 4). Following the 
termination of Boolean logic, this concept is referred to as AND-gate or AND-approach and 
has been shown to elicit specific activation (Wilkie et al., 2012; Kloss et al., 2013; Lanitis et 
al., 2013). Using this concept, full CAR T cell activation has been restricted to cells expressing 
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the PDAC antigens HER2 and MUC1 (Wilkie et al., 2012), PSCA and PSMA (Kloss et al., 
2013) and MSLN with folate receptor α (Lanitis et al., 2013). These systems using split main- 
and co-stimulating signal occasionally show activation when only a single target is presented, 
requiring affinity tuning and further modulations. This approach is currently investigated in a 
clinical setting using CD19 and a varying set of secondary antigens (NCT03125577).  
  
Figure 4: Increasing CAR T cell specificity by applying Boolean AND gates: Part I. From left to right: T cells 
expressing a second generation CAR are activated upon engaging with an antigen. When the main-stimulatory 
signal (CD3ζ) and the co-stimulatory signal (CO1) are split onto two CARs with differing specificity, single 
engagement of either target antigen 1 (green) or target antigen 2 (red) alone are not sufficient anymore to activate 
the CAR T cell. If both antigens are present on the target cell, main- and co-stimulatory signals are triggered again 
simultaneously, leading to a fully activated CAR T cell. scFv heavy chain (Vh) and light chain (Vl). Spacer (SP). 
Transmembrane domain (TM), Red boxes (ITAM).  
A more recent concept also follows the AND-gate logic, but with underlying temporal split 
mechanism (Fig. 5). The first receptor upon binding target 1 induces the expression of a fully 
functional CAR construct directed to target 2 (Roybal et al., 2016). This system employs 
synthetic Notch receptors (synNotch) that have been developed by the very same group before 
(Morsut et al., 2016). These synNotch receptors recognize tumor antigen 1, but unlike the above 
mentioned mechanism do not trigger T cell activation. Instead, a transcription factor is cleaved 
from the synNotch molecule. This transcription factor localizes to the nucleus and drives 
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expression of a CAR construct. This CAR is specific for tumor antigen 2 and now induces T 
cell activation and cytotoxicity (Fig. 5). While the synNotch system is shown to be not leaky in 
terms of activation in absence of one antigen, it is relatively stable, raising the concern that T 
cells may spread throughout the body and become active in unwanted regions before 
downregulation of the CAR.  
 
 Figure 5: Increasing CAR T cell specificity by applying Boolean AND gates: Part II.  The depicted system 
relies on synthetic Notch (synNotch) receptors (green). 1. An scFv directed to antigen 1 is connected to a Notch 
receptor. 2. Upon antigen 1 binding, enzymatic cleavage of the Notch receptor domain takes place and a 
transcription factor (TF) is released into the cytoplasm. 3. The TF diffuses into the nucleus and binds the promotor 
region of a CAR gene. 4. The CAR is transcribed and translated. 5. The CAR reaches the cell surface and now 
binds to antigen 2. Main-stimulatory signal (CD3ζ). Co-stimulatory signal (CO1). scFv heavy chain (Vh) and light 
chain (Vl). Spacer (SP). Transmembrane domain (TM), Red boxes (ITAM).  
Another combinatorial option could be overriding of the activation signal by a stronger 
inhibitory signal triggered by the detection of a second antigen (Fig. 6). These Boolean NOT 
combination is also known as iCARs (Fedorov et al., 2013). More precisely, the first CAR 
activates the T cell upon encounter of an antigen, which is expressed on tumor and healthy cells. 
On healthy but not tumor cells, a second antigen is expressed. A second CAR binds this antigen, 
but instead of conveying an activation signaling, this CAR evolves inhibitory signaling, 
stopping the whole CAR T cell from overcoming the activation threshold (Fig. 6). While this 
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principle allows for a rather sharp distinguishing of malignant and healthy tissue, this approach 
is not well investigated.   
In the context of this study, CLA could be used as an activating antigen. However, it is to be 
expected that toxicities could arise on leukocytes, which could be prevented by an inhibitory 
anti-CD45 CAR.  
        
Figure 6: Increasing CAR T cell specificity by applying a Boolean NOT gate. From left to right: T cells 
expressing a second generation CAR are activated upon engaging with an antigen. In addition to the second 
generation CAR directed against antigen 1, an inhibitory CAR (iCAR) specific for antigen 2 is introduced into the 
same T cell. The iCAR does not contain the classical main- (CD3ζ) and co-stimulatory (CO1) domains, but a 
deactivating or inhibitory domain (ID), for example derived from PD-1 or CTLA-4. Whenever antigen 2 is bound, 
the inhibitory signal overrides any positive signal, thus preventing CAR T cell activation. This mechanism can be 
applied in order to spare essential healthy cells, that share antigen 1 with the malignant cell. Target antigen 1 
(green). Target antigen 2 (red). scFv heavy chain (Vh) and light chain (Vl). Spacer (SP). Transmembrane domain 




5.1.2. Rational of CAR design and selection 
We chose a 4-1BB/CD3ζ second generation construct with a CD8α transmembrane domain for 
our CAR design, as those represent the current clinical standard for PDAC CAR T cell therapies 
(DeSelm et al., 2017). The variable regions of the light (Vl) and heavy chain (Vh) were derived 
from the antibodies used for target discovery and interconnected with a (G4S)3-linker. We 
constructed each CAR version with two differing scFv orientations, as it has been shown to 
affect binding and can lead to tonic signaling (Ajina and Maher, 2018). A common problem 
encountered with novel target epitopes is missing knowledge about the epitope’s position. 
Previous studies showed that the localization of the target epitope influences CAR function 
(Guest et al., 2005; Haso et al., 2013; Hudecek et al., 2013; Hudecek et al., 2015). Thus, we 
created a library of CARs specific for each target, using differing spacer lengths. In total, 34 
constructs were designed. In search for the most efficient CAR construct, we examined 
cytotoxicity, cytokine release and activation marker up-regulation. We found CD66c Vl-Vh XS, 
CD318 Vh-Vl XS, and TSPAN8 Vh-Vl S to be the most effective CAR constructs, with respect 
to our parameters. However, alternative parameters have been suggested as well, such as 
proliferation, phenotype or the ability to be stimulated several times (Davenport et al., 2015; 
Garfall et al., 2019). In fact, some of our chosen parameters might be correlated with 
disadvantageous clinical outcome. High cytokine release can lead to the cytokine release 
syndrome (CRS), one of the most severe side effects of CAR therapy (Brudno and 
Kochenderfer, 2016). Too strong T cell activation can lead to AICD and exhaustion (Künkele 
et al., 2015). Thus, it has to be evaluated, if this CAR selection process can also deliver the 
clinically most beneficial CAR construct. Nonetheless, our best performing CARs in vitro were 
also the best performing ones in vivo proving the applied strategy to be useful.  
5.2.3. Influence of the CAR spacer on CAR T cell functionality 
During our experimental in vitro assessment of the varying CAR constructs, it became apparent 
that the XS and S spacer performed almost indistinguishable good in the CD66c and CD318 
setting during the pre-assays, while TSPAN8 directed CARs performed best in S and L spacer 
configuration. Surprisingly, in the final assay comparing only CD66c XS and S spacer CAR, 
the XS spacer CAR showed no activity, although it has been functional before. The subsequent 
decision to perform in vivo experiments only with the S spacer was based on this experiment. 
A retrospective analysis however revealed a low transduction efficacy, making it likely, that 
the CD66c XS spacer CAR is still a potent CAR. Indeed, this was confirmed in a subsequent in 
vivo trial, which was not part of this study. These observations underline the hypothesis of an 
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optimal distancing between effector and target cell, as indicated by previous studies (Guest et 
al., 2005; James et al., 2008; Haso et al., 2013; Hudecek et al., 2013; Krenciute et al., 2016). 
This may be caused by the natural steric circumstances of T cell activation.  
The minimal components for T cell activation by natural TCR:MHC binding are well studied. 
The TCR binding to the MHC complex triggers the formation of a rigid and well-structured 
immunological synapse (Monks et al., 1998; Freiberg et al., 2002). This synapse is subdivided 
in three major supramolecular activation clusters (SMACs): central SMAC (cSMAC), 
peripheral (pSMAC) and distal (dSMAC). The TCR accumulates in the cSMAC, while in the 
dSMAC cell-cell attachment proteins cluster, like LFA-1 or CD2. In dSMAC, inhibitory 
phosphatases such as CD45 and CD148 are situated, which would otherwise prevent TCR/CD3 
phosphorylation (Onnis and Baldari, 2019). Each SMAC region on its own is dependent on 
defined distances between the antigen presenting cell and effector cell. In the central region, 
the distance is commonly 15 nm as dictated by the MHC:TCR complex (Garcia et al., 1996). 
Although a CAR synapse is less structured and seems to follow partially different requirements 
for activation, the distancing between CAR and epitope seems to generate higher activity when 
certain distance requirements are fulfilled (Guest et al., 2005; Haso et al., 2013; Hudecek et al., 
2013; Hudecek et al., 2015). This could be explained by the necessity of the CAR synapse to 
recapitulate the 15 nm distance of the TCR:MHC complex, in order to exclude deactivating 
phosphatases like CD45 and CD148, which both have longer extracellular stalks (Irles et al., 
2003; Cordoba et al., 2013). Although previous studies elaborated the importance of spacer 
length modulation in dependence to the target epitope, less diligence has been dedicated to 
clarify this issue. 
Although the exact position of the respective epitopes in our case is not known, some logical 
deductions can be performed (Fig. 7). The proteins of interest in this study contain either one 
extracellular single tail (CD66c and CD318) or two extracellular loops (TSPAN8) (The UniProt 
Consortium, 2019). The extracellular tail of CD318 consists of 638 amino acids (AAs) making 
it the longest peptide chain of the three targets. CD66c with 320 AAs has around half the amount 
of AAs. The extracellular loops of TSPAN8 span only 24 and 96 AAs and the bigger loop has 
interconnecting disulfide bridges further reducing the extent of the loop. As pure AAs numbers 
do not allow for reliable conclusions of a three-dimensional protein structure, the assumptions 
need to be further specified. The extracellular domains of CD66c are two C2-set Ig-like 
domains and one V-set Ig-like domain. All Ig-like proteins share a common structural basis. As 
the size is known to be approximately 5 nm from the constant heavy chain (CH) Ig domains 
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from antibodies (Harris et al., 1998; Ryazantsev et al., 2013; Wolak et al., 2015), it can be 
assumed that the total extracellular size of CD66c should be ~15 nm. Furthermore, it is known 
for the CD66c antibody used in this study, that the binding epitope is situated on the outer 
variable V-set domain. In conclusion, TSPAN8 represents a very membrane proximal target, 
while the CD66c epitope is located in approximately 15 nm distance from the membrane. For 
CD318, no estimation is applicable, however based on its size it is rather likely to have a 
membrane distal epitope. These different sized targets were now opposed by CAR constructs 
with varying spacer lengths. The spacers used were based on the human IgG4 hinge from the 
CH2-CH3 domains (L; long spacer; 228 AAs; ~10 nm), the human IgG4 hinge from the CH3 
domain (medium spacer; 119 AAs, ~5 nm), the human IgG4 hinge from the sequence between 
CH2 and CH1 domain (XS; extra short spacer; 12 AAs) or a human CD8α domain (S; short 
spacer; 45 AAs). 
As outlined before, the presumably ideal distance between a CAR T cell and target cell is 
~15 nm and the CD66c epitope might be ~15 nm distal from the membrane. Not surprisingly, 
the shortest CAR performed well, while the almost 15 nm spanning L spacer was inactive. 
Conversely, this spacer performed very good on the membrane-proximal TSPAN8, while the 
short spacer was dysfunctional in this setting. Of note, also surface protein CD318 was best 
targeted with the XS and S spacer.  
Why is the CD8α-derived S spacer able to engage both distal and proximal targets? A potential 
explanation for this phenomenon could be the structural nature of the CD8α spacer. For CH 
domain based IgG spacers, crystal structures are available. Their size is well known, forming a 
rigid three-dimensional structure. This is in contrast to the CD8α derived spacer. This spacer is 
derived from the stalk of the CD8α molecule, of which no structural information are available 
(Leahy et al., 1992). This is caused by the flexible nature of the stalk, making it impossible to 
crystallize. This fact may be the explanation for the versatility of this spacer by being flexible 
enough to convey binding over a broad range of distances.  
However, these explanations are based on cytotoxicity experiments and deduction from known 
sizes of related molecules. A real experimental proof for the mechanisms is missing. Future 
studies in this direction should focus less on effector functionality and more on the inter-cell 
distancing. High-resolution microcopy or electron microscopy would be suitable techniques to 






Figure 7: Hypothetical steric CAR:antigen interactions at a CAR synapse. The distance in a natural occurring 
immunological synapse is at the center supramolecular activation cluster (cSMAC) given through the steric 
interactions of the TCR:MHC complex. The distance of this complex is known to be approximately 15 nm (Garcia 
et al., 1996). This is important for T cell activation, as deactivating phosphatases like CD45 and CD148 are 
excluded from the cSMAC because their extracellular stalks are longer than these 15 nm. Hence, they are dispelled 
to regions with more space such as distal SMAC (Irles et al., 2003; Cordoba et al., 2013). This suggests the need 
of a CAR synapse to roughly recapitulate the steric situation of a natural occurring immunological synapse, in 
order to exclude CD45 and CD148. The size of the C-set Ig-like constant region domains (CH) of antibodies is 
also known to be approximately 5 nm (Harris et al., 1998; Ryazantsev et al., 2013; Wolak et al., 2015). Thus, a 
long IgG4 CH3-CH2 spacer can span ~10 nm, leaving ~ 5 nm for the scFv antigen interaction to match the optimal 
15 nm. In favor of this assumption are the efficacy data showing that only long TSPAN8 CARs activate T cells 
efficiently. CD66c consists of two C2-set domains and one V-set domain, the former ones being structural relatives 
of the CH domains. It can thus be assumed that they also extend to ~5 nm. As the epitope for the CD66c scFv is 
located on the membrane distal V-set domain, a CAR spacer needs to be short to recapitulate the 15 nm. Indeed, 
the long CAR spacers were not efficient at targeting CD66c. An exception is the CD8α spacer. CD8α spacer CARs 
perform well on membrane proximal and distal targets. Unsurprisingly, the CD8α stalk is known to be flexible 




5.2.4. A new class of Siglec derived CAR spacers 
When evaluated in our murine in vivo PDAC model, the L spacer CAR directed to TSPAN8 
only controlled tumor growth, while the S spacer CAR completely eradicated the tumors. This 
may be due to unspecific binding, as previous studies pointed out that unspecific binding of 
IgG1 and IgG4 based long spacers to Fc-receptors can hinder T cell function (Hombach et al., 
2010; Hudecek et al., 2015; Jonnalagadda et al., 2015). CH2 domains contain a binding moiety 
for Fc-receptors. However, T cell function can be rescued by mutating the binding regions, thus 
preventing unspecific interactions (Hombach et al., 2010; Hudecek et al., 2015; Jonnalagadda 
et al., 2015). Our IgG4 derived long spacer contained the very same mutations, which raised 
doubt if all unspecific interactions are abolished. We showed that PDAC xenograft tumors in 
NSG mice were well infiltrated by murine CD68+ macrophages, leaving the possibility of some 
remaining interactions between these murine immune cells and the CAR T cells. This concern 
was further nurtured by the complete failure of CAR T cell activity when we used a long IgG1 
spacer CAR in another experiment. While a CD20 targeting CAR based on a long IgG1 spacer, 
also containing previously reported mutations to abolish FcR binding, was indistinguishable 
effective from the S spacer based CAR on CD20+ lymphoma cells in vitro, it did not display 
efficacy in the subsequent in vivo study. This was even more surprising, considering that CD20 
is a membrane proximal target. Of note, no commercially approved CAR T cell product as of 
today is based on an IgG derived spacer. 
Due to these limitations, we aimed at creating a novel class of CAR spacer, having similar 
attributes as compared to IgG class spacer and analogous modularity. We screened naturally 
occurring protein families of immune cells and identified the Sialic acid-binding 
immunoglobulin-type lectin (Siglec) family as an auspicious alternative. Siglec molecules span 
a varying number of C2-set Ig-like domains between the membrane and the extracellular V-set 
binding domain (Macauley et al., 2014; Bornhöfft et al., 2018). However, in contrast to IgG, 
they naturally do not carry a FcR binding moiety, and – without few exceptions – are not known 
to convey binding offside the V-set domain. 
Alternative families with similar attributes that could have been considered as well, are the CEA 
family or Signaling lymphocytic activation molecule (SLAM) family. They also consist of 
differing numbers of C-set domains, have a V-set domain on the distal end and can thus be 




We selected one, two or three C2-set domains derived from Siglec-3, -4, -7, or -8 for generation 
of the new spacer library. One to three C-set domains have also been readily investigated in the 
context of IgG based spacer (Faitschuk et al., 2016; Watanabe et al., 2016). From the five CARs 
designed, only Siglec-4, Siglec -7.2 and Siglec -8 spacer CARs were found to be expressed on 
T cells. The Siglec-4 spacer CAR was singled out as the most effective one in co-culture 
experiments using CD20+ target cells and CD20 targeting CARs. Based on this finding, it was 
chosen for further investigation. However, the other two CARs – comprising Siglec-7.2 and 
Siglec-8 spacer – contained only one C2-set domain. Knowing about the optimal distancing 
between CAR T and target cell, this was a suboptimal setting as the CD20 antigen is located 
very membrane proximal. The very good performance of the Siglec-4 spacer CAR could be 
reproduced in a PDAC tumor mouse model, using a different membrane proximal target, 
namely TSPAN8. At the same time, this CAR was not able to develop a cytotoxic response 
when targeting CD66c, again supporting the model discussed above. Subsequent studies could 
either include Siglec-7.2 or Siglec-8 spacer CARs or Siglec-4 spacer CARs with only one C2-
set domain for targeting CD66c. While we could show that spacers derived from the Siglec 
family are effective CAR spacers, we did not prove the modularity of the spacer, meaning the 
adjustability towards targets with differing distances to the membrane. Future studies should 
elaborate these open questions to complete the toolbox of this new spacer family. 
Finally, the novel Siglec-4 spacer CARs induced in vitro a more beneficial cytokine release 
pattern and in vivo a phenotypic cell profile shifted towards the central memory T cell 
compartment as compared to the CD8α based CARs. This might have promising clinical 
implications, as massive cytokine release upon activation is one of the most severe side effects 
of current CAR therapies and an equally efficient CARs with lower cytokine release would 
decrease this risk for patients (Brudno and Kochenderfer, 2016). In addition, central memory T 
cells have been shown to convey a superior anti-tumor performance in contrast to cells shifted 
more to the effector compartment (Liu et al., 2020). Although promising, the underlying 
mechanisms are not yet understood, which is why these results need to be corroborated also in 
other target and indication settings to evaluate, if these beneficial traits can be retained.    




5.3. Conclusion and outlook 
The first two prospects of this study were the identification of novel target antigens for CAR 
based cellular therapy of PDAC with a safe off-tumor expression profile and the generation of 
functional CARs directed towards these novel target candidates. Four target candidates, namely 
CLA, CD318, CD66c and TSPAN8, were identified showing high tumor specificity and very 
restricted off-tumor expression. Although they appear with more favorable expression patterns 
than most other PDAC CAR targets, not all concerns could be resolved. An effective targeting 
of CLA requires the development of processes facilitating a functional knock-out of this 
glycosylation, while simultaneously preserving sufficient T cell transduction. Whereas CARs 
directed to CLA face technical roadblocks, CARs specific for CD318, CD66c and TSPAN8 
were able to evolve potent anti-tumor activity, both in vitro and in vivo. However, CD66c and 
TSPAN8 exhibit some limited but specific somatic-tissue expression, which could lead to 
toxicities when unmodified direct CAR T cells are administrated. This implies the necessity for 
further developments on strategies helping to avoid unwanted side-effects, in particular on-
target off-tumor toxicity. Advanced CAR engineering would be a promising option, in 
particular combinatorial logic gates, such as AND and NOT CARs. The usage of target 
combinations would further elevate CAR T cell specificity and the targets presented herein 
display normal tissue expression patterns suitable for such combinatorial approaches.  
This study showed that spacer modulation can induce significant differences regarding CAR 
activation, representing a valid option for CAR fine-tuning. The newly developed Siglec-4 
derived spacer bears the potential to help decreasing the risk of cytokine storm, possibly 
enabling to widen therapeutic window, which is a beneficial trait for potential clinical 
applications in the future. Whether this option is only available with the full-length spacer on 
membrane proximal targets or additionally on more distal epitopes, in case C2-set domains are 
removed, needs to be elucidated. Future studies addressing spacer related topics, would ideally 
make use of techniques enabling a direct read-out of the parameters of interest. High-resolution 
microcopy techniques are suitable to analyze distances between T cell and tumor cell or even 
interaction of molecules within a CAR synapse. A comprehensive knowledge of interactions 
among molecules involved in CAR synapse formation will help to advance our understanding 
on how CAR structural elements such as the spacer domains influence CAR functionality. 
This study describes four novel target candidates for CAR based cellular therapy of PDAC 
together with a set of highly functional CAR constructs. The thorough evaluation of somatic 
tissue expression will help to estimate and manage potential toxicities arising during clinical 
translation or even preventing those by next generation CAR design based on co-expression 
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patterns. In addition, a novel class of Siglec protein family derived spacers was introduced, with 
the Siglec-4 spacer exhibiting beneficial traits for potential clinical applications in the future.         
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